

PT New immunogenic peptides with HLA binding motif, useful in treatment
XX and diagnosis of cancers and viral diseases -

PS Claim 1; Page 80: 150pp; English.

CC AAY4390 to AAY48214 represent specifically claimed immunogenic peptides
CC having a human major histocompatibility complex (MHC) Class I (also
CC known as human leucocyte antigen (HLA)) binding motif. The immunogenic
CC peptides can bind to a specific HLA allele (i.e. HLA-A subtypes
CC HLA-A2, A1, A3, 2 or A24, 1 or HLA-B or C) and induce a cytotoxic T cell
CC response against the antigen from which the peptide is derived.
CC Cytotoxic T lymphocytes (CTLs) which destroy antigen-bearing cells are
CC normally induced by an antigen in the form of a peptide fragment bound
CC to a HLA molecule, rather than the intact foreign antigen itself, and
CC are particularly important in tumour rejection and in fighting viral
CC infections. The peptides are therefore useful therapeutically to treat
CC e.g. prostate cancer, hepatitis B and C, AIDS, and renal carcinoma.
CC They can be administered as vaccines to elicit an immune response in
CC individuals susceptible or otherwise at risk of viral infection or
CC cancer, or used to treat chronic or acute conditions. They are also
CC useful diagnostically, and can be used to induce a cytotoxic T cell
CC response, by contacting a cytotoxic T cell with the peptide e.g. to
CC produce CTLs ex vivo for infusion back into a patient. The
CC polynucleotides encoding the immunogenic peptides are also useful
CC therapeutically and for immunisation as above.

XX Sequence 1 AA;

Query Match Score 0; DB 20; Length 1;
Best Local Similarity 0.0%; Pred. No. 0;
Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 X 1
Db 1 Y 1

RESULT 2

ABB56870

Standard; Peptide; 1 AA.

ABB56870;

AC

DT

05-MAR-2002

(first entry)

DE Human SNP related amino acid sequence SEQ ID NO:1435.

XX Human; single nucleotide polymorphism; SNP; polymorphism; cytostatic;
KW immunosuppressive; antiinflammatory; neuroprotective; antimicrobial;
KW autoimmune disease; inflammation; cancer; nervous system disease;
infection; polymorphic protein.

OS Homo sapiens.

XX WO200138586-A2.

XX PD 31-MAY-2001.

XX PF 22-NOV-2000; 2000WO-US32311.

XX PR 24-NOV-1999; 99US-0167383.

XX PA (CURA-) CURAGEN CORP.

XX PI Shimkets RA, Leach M;

XX DR WPI; 2001-654860/75.

XX DR N-PSDB; ABL10912.

XX PR 23-MAR-2001; 2001WO-US59231.
XX PR 23-MAR-2000; 2000US-191637P.
XX PR 11-JUL-2000; 2000US-0614150.
XX PA (PEKE) PE CORP NY.

XX PI Venter JC, Adams M, Li PWD, Myers EW;

XX DR WPT; 2001-654860/75.

XX DR N-PSDB; ABL10912.

XX PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -

XX Disclosure; SEQ ID NO 27219; 21pp + Sequence Listing; English.

CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention

CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins
 CC (ABB5737-ABB7072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp://wipo.int/pub/published_pct_sequences.

XX Sequence 1 AA;

Query Match 0.0%; Score 0; DB 22; Length 1;
 Best Local Similarity 0.0%; Pred. No. 0;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 Qy 1 x 1
 Db 1 H 1

RESULT 4
 ID ABB66810 standard; Protein; 1 AA.
 XX
 AC ABB66810;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Drosophila melanogaster polypeptide SEQ ID NO 27222.
 XX
 KW Drosophila; developmental biology; cell signalling; insecticide;
 KW pharmaceutical.
 XX
 OS Drosophila melanogaster.
 XX
 PN WO200171042-A2.
 XX
 PD 27-SEP-2001.
 XX
 PF 23-MAR-2001; 2001WO-US09231.
 XX
 PR 23-MAR-2000; 2000US-191637P.
 PR 11-JUL-2000; 2000US-0614150.
 XX
 PA (PEKE) PE CORP NY.

XX Venter JC, Adams M, Li PWD, Myers EW;

XX PI WPI; 2001-656860/75.
 DR N-PSDB; ABL10913.
 XX
 PS Disclosure: SEQ ID NO 27222; 21pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins
 CC (ABB5737-ABB7072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp://wipo.int/pub/published_pct_sequences.

XX Sequence 1 AA;

Query Match 0.0%; Score 0; DB 22; Length 1;
 Best Local Similarity 0.0%; Pred. No. 0;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 x 1
 Db 1 H 1
 RESULT 5
 ID ABG02941 standard; Protein; 1 AA.
 XX
 AC ABG02941;
 XX
 DT 13-FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #2932.
 XX
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US08631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US-0649167.
 PA (HYSE) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 DR WPI; 2001-639362/73.
 DR N-PSDB; AAS67128.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity -

PS Claim 20; SEQ ID NO 33300; 103pp; English.

XX The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences, (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG10377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp://wipo.int/pub/published_pct_sequences.

XX Sequence 1 AA;
 Query Match 0.0%; Score 0; DB 22; Length 1;
 Best Local Similarity 0.0%; Pred. No. 0;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 x 1

XX	KW	Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic; neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer; amyloid protein; angiopoietin; apoptosis related protein; cadherin; cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor; complement related protein; cytochrome; kinesin; cytokine; interferon; interleukin; G-protein coupled receptor; thioesterase; inflammation; multifactorial disease; autoimmune disease; infection; nervous system disease.
XX	OS	Homo sapiens.
XX	PN	WO200147944-A2.
XX	PD	05-JUL-2001.
XX	PF	28-DEC-2000; 2000WO-US35498.
XX	PR	28-DEC-1999; 99US-0173419.
XX	PR	27-DEC-2000; 2000US-0173419.
XX	PA	(CURA-) CURAGEN CORP.
XX	PS	Shimkets RA, Leach M; Disclosure: Page 4045; 4143PP; English.
XX	DR	WPI: 2001-465210/50.
XX	CC	Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases, oncogenes and histones, useful for diagnosing and treating, e.g. cancer, autoimmune diseases and infections -
XX	CC	The present invention relates to oligonucleotides (see AAI26793-AAI34659) encoding polymorphic variants of proteins related to amylases, amyloid proteins, angiopoietin, apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes, histones, kinases, colony stimulating factors, complement related proteins, cytochromes, kinesins, cytokines, interferons interleukins, G-protein coupled receptors and thioesterases. The present sequence is a peptide encoded by one such oligonucleotide. The oligonucleotides and the peptides encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate expression of the proteins listed above. Disorders that may be prevented, diagnosed and/or treated include multifactorial diseases with a genetic component, such as autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus erythematosus and Grave's disease), inflammation, cancer (e.g. cancers of the bladder, brain, breast, colon and kidney, leukaemia), diseases of the nervous system and an infection of pathogenic organisms.

KW	quantitation; restorative therapy; polymorphic.
XX	
Homo sapiens.	
XX	WO200140521-A2.
XX	07-JUN-2001.
XX	30-NOV-2000; 2000WO-US32758.
XX	30-NOV-1999; 99US-0168138.
PR	29-NOV-2000; 2000US-0726173.
XXX	(CURA-) CURAGEN CORP.
PA	
PT	Shimkets RA, Leach M;
XX	
DR	WPI; 2001-356160/37.
XX	
PT	Polymorphic nucleic acid sequences, useful in gene therapy -
XX	
PS	Claim 29; Page 2619; 2653pp; English.
XX	
CC	AA179867 represent isolated human peptide sequences (1), which contain single nucleotide polymorphisms (AM53114 to AM53229) related to the polypeptide sequences. The sequences can be used in the prevention, diagnosis and the therapy, and in vaccine production. (1) and the CCC sequences may also be used in the prevention, diagnosis and the therapy, and in vaccine production. The sequences may be used with inappropriate expression of polypeptides by expressing inactive proteins or patients own production of polypeptide. Additional complementary sequences may also be used as DNA assays to detect and quantitate the presence of CC in samples, and therefore which patients may be therapy. The polypeptides encoded by (1) may be production of antibodies specific for polymorphic antibodies may also be used to down regulate expression. The antibodies may also be used as diagnostic aids presence of polymorphic polypeptides in samples.
CC	
CC	Sequence 1 AA;
SQ	Query Match 0 0%; Score 0; DB 22; ID 0.0%; Pred. No. 0; Mismatches 1;
CC	Best Local Similarity 0.04; Conservative 0; Mismatches 1;
CC	Matches 0;
CC	
Qy	1 X 1
Db	1 H 1
XX	
RESULT 12	
ID AAM53219	
ID AAM53219 standard; Peptide; 1 AA.	
XX	
AC AAM53219;	
XX	
AC	09-NOV-2001 (first entry)
XX	
DE Human nonconservative amino acid changing SNP re-	
XX	
DE Human single nucleotide polymorphism; SNP; gene	
XX	
KW protein therapy; vaccine; probe; diagnostic assay;	
KW quantitation; restorative therapy; polymorphic.	
XX	
OS Homo sapiens.	
XX	WO200140521-A2.
XX	

XX Polymorphic nucleic acid sequences, useful in genetic testing and
 PT therapy -
 XX Claim 29; Page 2641; 2653pp; English.
 XX AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide sequences (I), which contain single nucleotide polymorphisms (SNPs).
 CC AAM5114 to AAM53329 represent peptides related to human polymorphic polynucleotide sequences. The sequences can be used in gene and protein therapy, and in vaccine production. (I) and the polypeptides encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate expression of polymorphic polypeptides. For example, (I) may be used to treat disorders by rectifying mutations or deletions in a patient's genome that affect the activity of polypeptides by expressing inactive proteins or to supplement the patient's own production of polypeptide. Additionally, (I) and its complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The polypeptides encoded by (I) may be used as antigens in the production of antibodies specific for polymorphic polypeptides. The antibodies may also be used to down regulate expression and activity. The antibodies may also be used to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The polypeptides encoded by (I) may be used as antigens in the production of antibodies specific for polymorphic polypeptides. The antibodies may also be used to supplement the activity of restorative agents for detecting the presence of polymorphic polypeptides in samples.

XX SQ Sequence 1 AA;
 XX Query Match 0.0%; Score 0; DB 22; Length 1;
 XX Best Local Similarity 0.0%; Pred. No. 0;
 XX Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX Db 1 x 1
 XX
 XX SQ Sequence 1 AA;
 XX Query Match 0.0%; Score 0; DB 22; Length 1;
 XX Best Local Similarity 0.0%; Pred. No. 0;
 XX Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX Db 1 L 1

• RESULT 15
 AAM3328
 ID AAM3328 standard; Peptide: 1 AA.
 XX
 AC AAM53328;
 XX
 DT 09-NOV-2001 (first entry)
 XX DE Human nonconservative amino acid changing SNP related peptide SEQ:7023.
 XX KW Human; single nucleotide polymorphism; SNP; genome; gene therapy;
 KW protein therapy; vaccine; probe; diagnostic assay; detection;
 KW quantitation; restorative therapy; polymorphic.
 XX Homo sapiens.
 XX WO200140521-A2.
 XX 07-JUN-2001.
 XX 30-NOV-2000; 2000MO-US2758.
 XX 30-NOV-1999; 99US-0168138.
 XX 29-NOV-2000; 2000US-0726173.
 XX (CURA-) CURAGEN CORP.
 XX Shimkets RA, Leach M;
 XX
 XX WPI; 2001-356160/37.

XX Polymorphic nucleic acid sequences, useful in genetic testing and
 PT therapy -
 XX Claim 29; Page 2652; 2653pp; English.
 XX

CC AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide sequences (I), which contain single nucleotide polymorphisms (SNPs).
 CC AAM5114 to AAM53329 represent peptides related to human polymorphic polynucleotide sequences. The sequences can be used in gene and protein therapy, and in vaccine production. (I) and the polypeptides encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate expression of polymorphic polypeptides. For example, (I) may be used to treat disorders by rectifying mutations or deletions in a patient's genome that affect the activity of polypeptides by expressing inactive proteins or to supplement the patient's own production of polypeptide. Additionally, (I) and its complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The polypeptides encoded by (I) may be used as antigens in the production of antibodies specific for polymorphic polypeptides. The antibodies may also be used to down regulate expression and activity. The antibodies may also be used to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The polypeptides encoded by (I) may be used as antigens in the production of antibodies specific for polymorphic polypeptides. The antibodies may also be used to supplement the activity of restorative agents for detecting the presence of polymorphic polypeptides in samples.

CC SQ Sequence 1 AA;
 CC Query Match 0.0%; Score 0; DB 22; Length 1;
 CC Best Local Similarity 0.0%; Pred. No. 0;
 CC Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 CC
 CC Qy 1 x 1
 CC Db 1 v 1
 CC
 CC Search completed: February 12, 2003, 11:44:37
 CC Job time : 33 secs

CC -!- CATALYTIC ACTIVITY: ATP + an acid + protein = AMP + diphosphate + an acyl protein thioester.
 CC -!- PATHWAY: Bioluminescent fatty acid reduction system; second step.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement. (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
 CC
 EMBL; M62812; ; NOT_ANNOTATED_CDS.
 KW Luminescence; Ligase.
 FT NON_TER 1 1
 SEQUENCE 3 AA; 374 MW; 6AA3303000000000 CRR64;
 SQ

Query Match Score 0; DB 1; Length 3;
 Best Local Similarity 0.0%; Pred. No. 0;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 X 1
 DB 1 I 1

RESULT 3
 THYL_PIG STANDARD; PRT; 3 AA.
 AC P01151;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DIE Thyroliberin (Thyrotropin releasing hormone) (TRH) (Protirelin).
 OS Sus scrofa (Pig),
 Ovis aries (Sheep),
 OS Bombina orientalis (Oriental fire-bellied toad), and
 OS Notophthalmus viridescens (Eastern newt) (Triturus viridescens).
 OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC NCBI_TaxID:9823, 9940, 8346, 8316;
 RN [1]
 SEQUENCE.
 RC SPECIES-Pig; TISSUE=Hypothalamus;
 MEDLINE=10136150; PubMed=4384938;
 RX Nair R M G., Barrett J F., Bowers C.Y., Schally A.V.;
 RA "The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide.";
 RL Biochemistry 9:1103-1106(1970).
 RN [2]
 RP SYNTHESIS.
 SPECIES-Pig;
 MEDLINE=70039904; PubMed=4382117;
 RA Boller J., Enzmann F., Folkers K., Bowers C.Y., Schally A.V.;
 RT "The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide.";
 RL Biochem. Biophys. Res. Commun. 37:705-710(1969).
 RN [3]
 SEQUENCE-Sheep; TISSUE=Hypothalamus;
 RC Desiderio D.M. Jr., Burgus R., Dunn T.F., Vale W., Guillemin R., Ward D.N.;
 RA "The elucidation of the primary structure of the hypothalamic thyroid stimulating hormone releasing factor of ovine origin by means of mass spectrometry";
 RL Org. Mass Spectrom. 5:221-228(1971).
 RN [4]
 SYNTHESIS.
 SPECIES-Sheep;
 MEDLINE=70163386; PubMed=4385794;
 RA Burgus R., Dunn T.F., Desiderio D.M., Ward D.N., Vale W., Guillemin R.;
 RT "Characterization of ovine hypothalamic hypophysiotropic TSH-releasing factor.";

RL Nature 226:321-325(1970).
 RN [5]
 SEQUENCE.
 RC SPECIES=B.orientalis; TISSUE=Skin;
 RX MEDLINE=76138399; PubMed=815011;
 RA Yasuhara T., Nakajima T.;
 RT "Letter: Occurrence of PYR-His-Pro-NH₂ in the frog skin.";
 RL Chem. Pharm. Bull. 23:3301-3303(1975).
 RN [6]
 SEQUENCE.
 RP MEDLINE=7505605; PubMed=4214528;
 RX Grimm-Joergensen Y., McKelvy J.P.;
 RA "Biogenesis of thyrotropin releasing factor by newt (Triturus viridescens) brain in vitro. Isolation and characterization of thyrotropin releasing factor.";
 RT J. Neurochem. 23:471-478(1974).
 CC -!- FUNCTION: TRH FUNCTIONS AS A REGULATOR OF THE BIOSYNTHESIS OF TSH IN THE ANTERIOR PITUITARY GLAND AND AS A NEUROTRANSMITTER/NEUROMODULATOR IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS.
 CC PIR: A01415; RHPTC;
 DR PIR; A93750; RHSHT;
 DR PIR; A90919; RHPTD0;
 DR PIR; A92971; A92971;
 KW Amidation.
 FT MOD_RES 1 1
 FT MOD_RES 3 3
 SQ SEQUENCE 3 AA; 380 MW; 7761F6B0000000000 CRC64;
 SQ

Query Match Score 0; DB 1; Length 3;
 Best Local Similarity 0.0%; Pred. No. 0;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 X 1
 DB 1 Q 1

RESULT 4
 ACH1_ACHFU STANDARD; PRT; 4 AA.
 ID ACH1_ACHFU
 AC P35904;
 DT 01-JUN-1994 (Rel. 29, Created)
 DT 01-JUN-1994 (Rel. 29, Last sequence update)
 DT 15-JUL-1998 (Rel. 36, Last annotation update)
 DE Achatin-I.
 OS Achatina fulica (Giant African snail).
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Styliommatophora; Achatinacea; Achatinidae; Achatina.
 OC NCBI_TaxID:6530;
 OX RN [1]
 SEQUENCE, CHARACTERIZATION, AND SYNTHESIS.
 RC STRAIN-Ferussac; TISSUE=Gastrop.
 MEDLINE=89233551; PubMed=2557281;
 RX RA Kamatani Y., Minakata H., Kenny P.T.M., Iwashita T., Watanabe K.,
 RA Funase K., Sun X.P., Yongsiri A., Kim K.H., Novales Li P.,
 RA Novales E.T., Kanata C.G., Takeuchi H., Nomoto K.;
 RA "Achatin-I, an endogenous neuroexcitatory tetrapeptide from Achatina fulica. Ferussac containing a D-amino acid residue.";
 RL Biochem. Biophys. Res. Commun. 160:1015-1020(1989).
 RN [2]
 CHARACTERIZATION.
 RC STRAIN-Ferussac; TISSUE=Heart atrium;
 RX RA Fujimoto K., Kubota I., Yasuda K., Minakata H., Nomoto K.,
 RA Yoshida M., Harada A., Muneoka Y., Kobayashi M.;
 RT "Purification of achatin-I from the atria of the African giant snail, Achatina fulica, and its possible function";
 RL Biochem. Biophys. Res. Commun. 177:847-855(1991).
 RN [3]
 X-RAY CRYSTALLOGRAPHY.
 MEDLINE=93014529; PubMed=1399265;
 RX RA Ishida T., In Y., Doi M., Inoue M., Yasuda Kamatani Y., Minakata H.,

Iwashita T.; Nomoto K.; "Crystal structure and molecular conformation of achatin-I (H-Gly-D-Phe-Ala-Asp-OH), an endogenous neuropeptide containing a D-amino acid residue."; Int. J. Pept. Protein Res. 39: 258-264 (1992); -!- FUNCTION: NEUROEXCITATORY PEPTIDE; INCREASES THE IMPULSE FREQUENCY OF THE IDENTIFIED HEART EXCITATORY NEURON (PON); ALSO ENHANCES THE AMPLITUDE AND FREQUENCY OF THE HEART BEAT. HAS ALSO AN EFFECT ON SEVERAL OTHER MUSCLES. PIR: A32480; A32480. Hormone; D-amino acid. MOD_RES 2 2 D-PHENYLALANINE; SEQUENCE 4 AA; 408 MW; 6AADDYC810000000 CRC64;		DE dehydrogenase subunit S (CO-DH S) (Fragment). GN CNTS. OS Pseudomonas carboxydohydrogenase. OC Bacteria; Proteobacteria; alpha subdivision; Rhizobiaceae group. OC Bradyrhizobium group. NCBI_TAXID=290; RN [1] SEQUENCE; MEDLINE=90055678; PubMed=2818128; RX RA Kraut M.; Hugendieck I.; Herwig S.; Meyer O.; RA "Homology and distribution of CO dehydrogenase structural genes in carboxydotrophic bacteria."; RT Arch. Microbiol. 152:335-341(1989). CC -!- FUNCTION: Catalyzes the oxidation of carbon monoxide to carbon dioxide. CC -!- CATALYTIC ACTIVITY: CO + H(2)O + acceptor = CO(2) + reduced acceptor. CC -!- COFACTOR: BINDS TWO 2FE-2S CLUSTERS. CC -!- SUBUNIT: CONSISTS OF THREE POLYPEPTIDE CHAINS: LARGE, MEDIUM, AND SMALL. DR PIR; PLO146; PL0146. KW Oxidoreductase; Iron-sulfur. FT NON_TER 4 4 SQ SEQUENCE 4 AA; 420 MW; 6DD33D6F0000000 CRC64;	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; 1 X 1 3 A 3		Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps		Qy 1 X 1 Db 2 A 2	
RESULT 5 DML_PSECH P19916; 01-FEB-1991 (Rel. 17, Created) 01-FEB-1991 (Rel. 17, Last sequence update) 15-JUN-2002 (Rel. 41, Last annotation update) Carbon monoxide dehydrogenase large chain (EC 1.2.99.2) (CO dehydrogenase subunit L) (CO-DH L) (Fragment). CURL		RESULT 7 EOST_HUMAN ID EOST_HUMAN STANDARD; PRT; 4 AA. AC P02731; DT 21-JUL-1986 (Rel. 01, Created) DT 21-JUL-1986 (Rel. 01, Last sequence update) DT 21-JUL-1986 (Rel. 01, Last annotation update) DE Eosinophilic tachykinins. OS Homo sapiens (Human). OC Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarhini; Hominidae; Homo. NCBI_TAXID=99606; RN [1] RP SEQUENCE; RX MEDLINE=16078412; PubMed=1060093; RA Getzl E. J.; Austen K. F.; RT "Purification and synthesis of eosinophilic tachykinins of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis". RT anaphylaxis". RL Proc. Natl. Acad. Sci. U.S.A. 72:4123-4127 (1975). CC -!- MISCELLANEOUS: THESE PEPTIDES ARE RELEASED FROM MAST CELLS IN LUNG (AND OTHER TISSUES) DURING HYPERSENSITIVITY REACTIONS CC (ANAPHYLAXIS). THEIR ACTIVITIES, PREFERENTIALLY AFFECTING EOSINOPHILS, INCLUDE CHEMOTAXIS, CHEMOTACTIC DEACTIVATION, RELEASE OF ENZYMES, AND STIMULATION OF THE HEXOSE MONOPHOSPHATE SHUNT. CC PIR; A03190; ETHUL. 1 1 V -> A (IN OTHER PEPTIDE). DR VARIANT 1 1 FT /FTIG-YVAR_005201. SQ SEQUENCE 4 AA; 390 MW; 6B05B862A0000000 CRC64;	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps		Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps		Qy 1 X 1 Db 3 S 3	
RESULT 6 DMS_PSECH P19918; 01-FEB-1991 (Rel. 17, Created) 01-FEB-1991 (Rel. 17, Last sequence update) 15-JUN-2002 (Rel. 41, Last annotation update) Carbon monoxide dehydrogenase small chain (EC 1.2.99.2) (CO		DE dehydrogenase subunit S (CO-DH S) (Fragment). GN CNTS. OS Pseudomonas carboxydohydrogenase. OC Bacteria; Proteobacteria; alpha subdivision; Rhizobiaceae group. OC Bradyrhizobium group. NCBI_TAXID=290; RN [1] SEQUENCE; MEDLINE=90055678; PubMed=2818128; RX RA Kraut M.; Hugendieck I.; Herwig S.; Meyer O.; RA "Homology and distribution of CO dehydrogenase structural genes in carboxydotrophic bacteria."; RT Arch. Microbiol. 152:335-341(1989). CC -!- FUNCTION: Catalyzes the oxidation of carbon monoxide to carbon dioxide. CC -!- CATALYTIC ACTIVITY: CO + H(2)O + acceptor = CO(2) + reduced acceptor. CC -!- COFACTOR: Molibdenum (molybdopterin). CC -!- SUBUNIT: CONSISTS OF THREE POLYPEPTIDE CHAINS: LARGE, MEDIUM, AND SMALL. DR PIR; PLO140; PL0140. KW Oxidoreductase; Molibdenum. FT NON_TER 4 4 SQ SEQUENCE 4 AA; 441 MW; 7761EB76F0000000 CRC64;	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps		Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps	
Query Match 0.0%; Score 0; DB 1; Length 4; Best Local Similarity 0.0%; Pred. No. 0; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps		Qy 1 X 1 Db 3 S 3	

RESULT 8	FAR3_HIRME	STANDARD;	PRT;	4 AA.	
ID	FAR3_HIRME				
AC	P4262;				
DT	01-NOV-1995 (Rel. 32, Created)				
DT	01-NOV-1995 (Rel. 32, Last sequence update)				
DT	01-NOV-1995 (Rel. 32, Last annotation update)				
DE	FMRFamide-like neuropeptide YURF amide.				
OS	Hirudo medicinalis (Medicinal leech).				
OC	Arachnophorida; Hirudiniformes; Hirudinida; Hirudo.				
OC	Metazoa; Annelida; Clitellata; Hirudinida; Hirudo.				
OX	NCBI_TaxID:6421; [1]				
RN	RP				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. ";				
RL	Peptides 12:897-908(1991).				
CC	-!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE)				
CC	FAMILY.				
KW	Neuropeptide; Amidation.				
FT	MOD_RES 4 4 AMIDATION.				
SEQUENCE	4 AA; 598 MW; 69D4073B30000000 CRC64;				
	Query Match Best Local Similarity 0.0%; Score 0; DB 1; Length 4; Matches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy	1 X 1				
Db	1 Y 1				
RESULT 9	FAR4_HIRME	STANDARD;	PRT;	4 AA.	
ID	FAR4_HIRME				
AC	P42563;				
DT	01-NOV-1995 (Rel. 32, Created)				
DT	01-NOV-1995 (Rel. 32, Last sequence update)				
DT	01-NOV-1995 (Rel. 32, Last annotation update)				
DE	FMRFamide-like neuropeptide YMRF-amide.				
OS	Hirudo medicinalis (Medicinal leech).				
OC	Arachnophorida; Hirudiniformes; Hirudinida; Hirudo.				
OC	Metazoa; Annelida; Clitellata; Hirudinida; Hirudo.				
OX	NCBI_TaxID:6421; [1]				
RN	RP				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. ";				
RL	Peptides 12:897-908(1991).				
CC	-!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE)				
CC	FAMILY.				
KW	Neuropeptide; Amidation.				
FT	MOD_RES 4 4 AMIDATION.				
SEQUENCE	4 AA; 616 MW; 69D4068B30000000 CRC64;				
	Query Match Best Local Similarity 0.0%; Score 0; DB 1; Length 4; Matches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy	1 X 1				
Db	1 Y 1				
RESULT 10	PFKA_ANTEL	STANDARD;	PRT;	4 AA.	
ID	PFKA_ANTEL				
AC	P58705;				
DT	15-JUN-2002 (Rel. 41, Created)				
DT	15-JUN-2002 (Rel. 41, Last sequence update)				
DT	15-JUN-2002 (Rel. 41, Last annotation update)				
DE	Antho-KAamide.				
OS	Anthoporeura elegantisima (Sea anemone).				
OC	Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actinaria.				
OC	Nyantheae; Actiniidae; Anthopleura.				
NCBI_TaxID:6110; [1]					
RN	RP				
SEQUENCE					
RX	MEDLINE=2028852; PubMed=1681803;				
RA	Nothacker H.-P., Rinehart K.L., Jr., Grimmelikhuijen C.J.P.;				
RT	"Isolation of L-3-phenylalactyl-Phe-Lys-Ala NH2 (Antho-KAamide), a novel neuropeptide from sea anemones. "				
RL	Biochem. Biophys. Res. Commun. 179:1205-1211(1991).				
RL	Biochem. Biophys. Res. Commun. 179:1205-1211(1991).				
RN	[2]				
FUNCTION					
RX	MEDLINE=33391436; PubMed=8397415;				
RA	McFarlane J.D., Hudman D., Nothacker H.-P., Grimmelikhuijen C.J.P.;				
RT	"The expansion behaviour of sea anemones may be coordinated by two inhibitory neuropeptides, Antho-KAamide and Antho-KAamide. "				
RL	Proc. R. Soc. Lond., B, Biol. Sci. 255:183-188(1993).				
CC	-!- FUNCTION: Inhibits spontaneous contractions in several muscle groups. May be involved in the expansion phase of feeding behaviour in sea anemones.				
CC	-!- SUBCELLULAR LOCATION: Secreted.				
CC	-!- TISSUE SPECIFICITY: Neuron-specific.				
KW	Neuropeptide; Amidation.				
FT	MOD_RES 1 1 L-3-PHENYLALACTYL.				
FT	MOD_RES 4 4 AMIDATION.				
SEQUENCE	4 AA; 512 MW; 6DD339C9A0000000 CRC64;				
	Query Match Best Local Similarity 0.0%; Score 0; DB 1; Length 4; Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
Qy	1 X 1				
Db	4 A 4				
RESULT 11	FLRF_HIRME	STANDARD;	PRT;	4 AA.	
ID	FLRF_HIRME				
AC	P42561;				
DT	01-NOV-1995 (Rel. 32, Created)				
DT	01-NOV-1995 (Rel. 32, Last sequence update)				
DT	01-NOV-1995 (Rel. 32, Last annotation update)				
DE	FLRFamide.				
OS	Hirudo medicinalis (Medicinal leech), and				
OS	Helisoma trivolvis (Snail)				
OC	Eukaryota; Metazoa; Annelida; Clitellata; Hirudinida; Hirudiniformes; Hirudinidae; Hirudinidae; Hirudo.				
OC	Arachnophorida; Hirudiniformes; Hirudinida; Hirudo.				
OX	NCBI_TaxID=6421; 27815; [1]				
RN	RP				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[1]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[2]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[3]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[4]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[5]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[6]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[7]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[8]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[9]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[10]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[11]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[12]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[13]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[14]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[15]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[16]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[17]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[18]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[19]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[20]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[21]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[22]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-908(1991).				
RN	[23]				
SEQUENCE					
RX	MEDLINE=92195954; PubMed=1686933;				
RA	Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;				
RT	"Identification of RFamide neuropeptides in the medicinal leech. "				
RL	Peptides 12:897-9				

Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Indels 1; Gaps 0; RT "Purification and characterization of a cardioexcitatory neuropeptide from the central ganglia of a bivalve mollusc.";
 Matches 0; Conservative 0; RT
 Qy 1 X 1 RT
 Db 1 F 1 RT
 RN [3]
 RESULT 12 FLRN_ANTEL STANDARD; PRT; 4 AA.
 ID FLRN_ANTEL
 AC P58707;
 DT 15-JUN-2002 (Rel. 41, Created)
 DT 15-JUN-2002 (Rel. 41, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Antho.RNamide.
 VS Anthopleura elegantissima (Sea anemone).
 OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actiniaria;
 NC Nyanthaeae; Actiniidae; Anthopleura.
 OX NCBI_TAXID=6110;
 RN [1]
 RP SEQUENCE, AND MASS-SPECTROMETRY.
 RX MEDLINE=9019122; PubMed=1973541;
 RA Grimmelikhuijen C.J.P., Rinehart K.L. Jr., Graff D.,
 Reinscheid R.K., Nothacker H.-P., Staley A.L.;
 RT "Isolation of L-3-phenylalanyl-leu-Arg-Asn-NH2 (Antho-RNamide), a sea anemone neuropeptide containing an unusual amino-terminal blocking group.";
 RT Proc. Natl. Acad. Sci. U.S.A. 87:5410-5414 (1990).
 CC 1- SUBCELLULAR LOCATION: Secreted.
 CC 1- TISSUE SPECIFICITY: Neuron specific.
 CC 1- MASS SPECTROMETRY: Mw=549.3; METHOD=FAB.
 KW Neuropeptide; Amidation.
 FT MOD_RES 1 1 L-3-PHENYLALACTYL.
 FT MOD_RES 4 4 AMIDATION.
 SQ SEQUENCE 4 AA; 549 MW; 64540729A0000000 CRC64;
 Query Match 0.0%; Score 0; DB 1; Length 4;
 Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Indels 1; Gaps 0; RT
 Matches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0; RT
 Qy 1 X 1 RT
 Db 1 F 1 RT
 RESULT 13 FMRF_MACN1 STANDARD; PRT; 4 AA.
 ID FMRF_MACN1
 AC P01162;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-JUL-1998 (Rel. 36, Last annotation update)
 DE FMRFamide (Peak C) (Cardioexcitatory neuropeptide).
 OS Macrocallista nimbosa (Sun-ray clam),
 OS Nereis virens (Sandworm),
 OS Hirudo medicinalis (Medicinal leech), and
 OS Helisoma trivolvis (snail).
 OC Eukaryota; Metazoa; Mollusca; Bivalvia; Heteroconchia; Veneroida;
 OC Veneroidea; Veneridae; Macrocallista.
 OX NCBI_TAXID=6594;
 RN [1]
 RP SEQUENCE, AND SYNTHESIS.
 RC SPECIES=M. nimbosa; TISSUE=Cerebral pedal, and Visceral ganglion;
 RX MEDLINE=78012038; PubMed=909875;
 RA Price D.A., Greenberg M.J.;
 RT "Structure of a molluscan cardioexcitatory neuropeptide.";
 RL Science 197:670-671 (1977).
 RN [2]
 RP SEQUENCE, AND CHARACTERIZATION.
 RC SPECIES=M. nimbosa; TISSUE=Ganglion;
 RX MEDLINE=7215956; PubMed=877582;
 RA Price D.A., Greenberg M.J.;
 RP FUNCTION.
 RX MEDLINE=93391436; PubMed=8397415;
 RA McFarlane I.D., Hudman D., Notthacker H.-P., Grimmelikhuijen C.J.P.;
 RC "The expansion behaviour of sea anemones: the unusual, RT
 RT "Isolation of two novel neuropeptides from sea anemones: the unusual, RT
 RT biologically active L-3-phenylalanyl-Tyr-Arg-Tie-NH2 and its RT
 RT des-phenylalanyl fragment Tyr-Arg-Tie-NH2.";
 RL Peptides 12:1165-1173 (1991).
 RN [2]
 RP FUNCTION.
 RX MEDLINE=93391436; PubMed=8397415;
 RA McFarlane I.D., Hudman D., Notthacker H.-P., Grimmelikhuijen C.J.P.;
 RC "The expansion behaviour of sea anemones: the unusual, RT
 RT "Isolation of two novel neuropeptides, Antho-RNamide and Antho-RRamide.";
 RL Proc. R. Soc. Lond., B, Biol. Sci. 253:183-188 (1993).
 RN [3]
 RP SEQUENCE.
 RC SPECIES=H. medicinalis;
 RX MEDLINE=92115954; PubMed=1686933;
 RA Evans B.D., Pohl J., Kartsonis M.A., Calabrese R.L.;
 RT "Identification of FMRFamide neuropeptides in the medicinal leech.";
 RL Peptides 12:897-908 (1991).
 RN [5]
 RP SEQUENCE.
 RC SPECIES=H. trivolvis; TISSUE=Kidney;
 RX MEDLINE=94286417; PubMed=712428;
 RA Madrid K.P., Price D.A., Greenberg M.J., Khan H.R., Saleuddin A.S.M.;
 RT "FMRFamide-related peptides from the kidney of the snail, Helisoma trivolvis.";
 RT Peptides 15:31-36 (1994).
 RL -!- FUNCTION: MYOACTIVE; CARDIOEXCITATORY SUBSTANCE. PHARMACOLOGICAL ACTIVITIES INCLUDE AUGMENTATION, INDUCTION, AND REGULARIZATION OF CARDIAC CONTRACTION.
 CC -!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE) FAMILY.
 CC PIR; A01426; ECNK.
 DR PIR; A60418; A60418.
 KW Neuropeptide; Amidation.
 FT MOD_RES 4 4 AMIDATION.
 SQ SEQUENCE 4 AA; 600 MW; 69D40699A0000000 CRC64;
 Query Match 0.0%; Score 0; DB 1; Length 4;
 Best Local Similarity 0.0%; Score 0; DB 1;
 Matches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 X 1 RT
 Db 1 F 1 RT
 RESULT 14 FYRL_ANTEL STANDARD; PRT; 4 AA.
 ID FYRL_ANTEL
 AC P38706;
 DT 15-JUN-2002 (Rel. 41, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Antho-RRamide I (Contains Antho-RIamide II).
 OS Anthopleura elegantissima (Sea anemone).
 OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actiniaria;
 OC Nyanthaeae; Actiniidae; Anthopleura.
 OX NCBI_TAXID=6110;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=92270459; PubMed=1821096;
 RA Nothacker H.-P., Rinehart K.L. Jr., McFarlane I.D.,
 RA Grimmelikhuijen C.J.P.;
 RT "Isolation of two novel neuropeptides from sea anemones: the unusual, RT
 RT biologically active L-3-phenylalanyl-Tyr-Arg-Tie-NH2 and its RT
 RT des-phenylalanyl fragment Tyr-Arg-Tie-NH2.";
 RL Peptides 12:1165-1173 (1991).
 RN [2]
 RP FUNCTION.
 RX MEDLINE=93391436; PubMed=8397415;
 RA McFarlane I.D., Hudman D., Notthacker H.-P., Grimmelikhuijen C.J.P.;
 RC "The expansion behaviour of sea anemones: the unusual, RT
 RT "Isolation of two novel neuropeptides, Antho-RNamide and Antho-RRamide.";
 RL Proc. R. Soc. Lond., B, Biol. Sci. 253:183-188 (1993).
 RN [3]

CC -!- FUNCTION: Inhibits spontaneous contractions in several muscle groups. May be involved in the expansion phase of feeding behaviour in sea anemones.

CC -!- SUBCELLULAR LOCATION: Secreted.

CC -!- TISSUE SPECIFICITY: Neuron-specific.

DR InterPro: IPR001023; Hsp70.

KW Neuropeptide; Amidation.

FT CHAIN 1 ANTHO-RIAMIDE I.

FT CHAIN 2 ANTHO-RIAMIDE II.

FT MOD_RES 1 1 L-3-PHENYLALACTYL.

FT MOD_RES 4 4 AMIDATION.

SO SEQUENCE 4 AA; 598 MW; 60441B59A000000 CRC64;

Query Match 0.0%; Score 0; DB 1; Length 4;

Best Local Similarity 0.0%; Pred. No. 0;

Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 x 1

Db 1 F 1

RESULT 15

CC OCP1_OCTMI STANDARD; PRT; 4 AA.

AC P58648;

DT 15-JUN-2002 (Rel. 41, Created)

DT 15-JUN-2002 (Rel. 41, Last sequence update)

DT 15-JUN-2002 (Rel. 41, Last annotation update)

DE Cardioactive Peptides Ocp-1/Ocp-2.

OS Octopus minor (Octopus)

OC Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Octopoda; Incirrata; Octopodidae; Octopus;

OX NCBL_TAXID=89766;

RN [1]

RP SEQUENCE, SYNTHESIS, MASS SPECTROMETRY, AND CHARACTERIZATION.

RC TISSUE=Brain;

RX MEDLINE=20336815; PubMed=10876044;

RA Iwakoshi E., Hisada M., Minakata H.;

RT "Cardioactive peptides isolated from the brain of a Japanese octopus, Octopus minor."

RL Peptides 21:623-630(2000).

CC -!- FUNCTION: Cardioactive; has both positive chronotropic and inotropic effects on the heart. Ocp-2 is a 1000 time less active than Ocp-1.

CC -!- SUBCELLULAR LOCATION: Secreted.

CC -!- PTM: Ocp-2 has L-Phe instead of D-Phe.

CC -!- MASS SPECTROMETRY: MW=395.2; METHOD=MALDI.

KW Hormone; D-amino acid.

FT MOD_RES 2 D-PHENYLALANINE.

SO SEQUENCE 4 AA; 394 MW; 6AA879C81000000 CRC64;

Query Match 0.0%; Score 0; DB 1; Length 4;

Best Local Similarity 0.0%; Pred. No. 0;

Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 x 1

Db 1 G 1

Result No.	Score	Query	Match	Length	DB	ID	Description
1	0	0.0	4	11	Q08433	Q08433 rattus norvegicus	
2	0	0.0	5	2	P83073	P83073 bacillus cereus	
3	0	0.0	5	10	Q99007	Q99007 hordeum vulgare	
4	0	0.0	5	13	P83308	P83308 gallus gallus	
5	0	0.0	6	10	P82181	P82181 spinacia olar	
6	0	0.0	6	10	P82541	P82541 spinacia olar	
7	0	0.0	6	10	P82182	P82182 spinacia olar	
8	0	0.0	7	2	007354	007354 synchococcus	
9	0	0.0	7	2	047029	047029 enterobacter	
10	0	0.0	7	2	050556	050556 actinobacil	
11	0	0.0	7	2	034028	034028 sphingomonas	
12	0	0.0	7	2	047477	047477 escherichia	
13	0	0.0	7	2	047505	047505 escherichia	
14	0	0.0	7	2	P70804	P70804 azotobacter	
15	0	0.0	7	2	Q54248	Q54248 streptomyces	
16	0	0.0	7	2	P72081	P72081 nocardia la	

Db	1	N	1
RESULT 2			
ID	P83073	PRELIMINARY;	PRT;
AC	P83073;	5 AA.	
DT	01-OCT-2001 (TREMBLrel. 18, Created)		
DT	01-OCT-2001 (TREMBLrel. 18, Last sequence update)		
DT	01-OCT-2001 (TREMBLrel. 18, Last annotation update)		
DT	01-OCT-2001 (TREMBLrel. 18, Last annotation update)		
DE	Bacillus cereus.		
OS	Bacteria; Firmicutes; Bacillus/Clostridium group; Bacillales;		
OC	Bacillaceae; Bacillus.		
OC	NCBI_TaxID=1396; [1]		
RN		RN [1]	
RP		RP	
SEQUENCE		SEQUENCE, AND SYNTHESIS.	
RC	STRAIN=NCIMB 11796;	RC TISSUE=BRAIN;	
RA	Browne N., Dowds B.C.A.;	Pubmed=6137771;	
RA	Submitted (JUL-2001) to the SWISS-PRON data bank.	RA Dockray G.J., Reeve J.R. Jr., Shively J., Gayton R.J., Barnard C.S.;	
FT	NON_TER 5	FT "A novel active pentapeptide from chicken brain identified by antibodies to FMRFamide.";	
SQ	SEQUENCE 5 AA: 623 MW;	FT RT	
Query Match	0.0%	Nature 305:328-330(1993).	
Best Local Similarity	0.0%	CC -!- FUNCTION: MAY FUNCTION AS A NEUROTRANSMITTER OR MODULATOR.	
Matches	0;	CC -!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE) FAMILY.	
QY	1 X 1	KW Neuropeptide.	
Db	4 T 4	SQ Sequence 5 AA: 645 MW;	69d4073767400000 CRC64;
RESULT 3			
ID	Q99007	PRELIMINARY;	PRT;
AC	Q99007;	5 AA.	
DT	01-NOV-1996 (TREMBLrel. 01, Created)		
DT	01-NOV-1996 (TREMBLrel. 01, Last sequence update)		
DT	01-NOV-1998 (TREMBLrel. 08, Last annotation update)		
DE	Alpha-amylase (EC 3.2.1.1) (Fragment).		
GN	AMYL.		
OS	Hordeum vulgare (Barley).		
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
OC	Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooidae;		
OC	Triticaceae; Hordeum.		
OX	NCBI_TaxID=4513; [1]		
RN		RNA	
RP	SEQUENCE FROM N. A. TISSUE=ALEURONE LAYER;	SEQUENCE-CV. ALWARO; TISSUE=LEAF;	
RC	STRAIN="HIMALAYA"; PUBMED=91329704; PUBLISHED=1831055;	RP STAIN-CV. ALWARO; TISSUE=LEAF;	
RX	Jacobsen J.V., Close T.J.;	RC MEDLINE=20435798; PubMed=10874046;	
"Control of transient expression of chimaeric genes by gibberellic acid and gibberellin acid in protoplasts prepared from mature barley aleurone layers.";			
RT	Plant Mol. Biol. 16:713-721(1991).	RC Yamaguchi K., Subramanian A.R.;	
CC	-!- CATALYTIC ACTIVITY: ENDOHYDROLYSIS OF 1,4-ALPHA-GLUCOSIDIC LINKAGES IN OLIGOSACCHARIDES AND POLYSACCHARIDES.	RT "The plastid ribosomal proteins. Identification of all the proteins in the 50 S subunit of an organelle ribosome (chloroplast).";	
CC	-!- COFACTOR: BINDS A CALCIUM ION REQUIRED FOR ITS ACTIVITY.	RT RL J. Biol. Chem. 275:2846-2848(2000).	
CC	-!- MISCELLANEOUS: THERE ARE AT LEAST 4 TYPES OF ALPHA-AMYLASE IN BARLEY.	CC CC -!- FUNCTION: THIS PROTEIN BINDS DIRECTLY TO 23S RIBOSOMAL RNA.	
EMBL	X54643; CAA18455.1; [1]	CC CC -!- SUBCELLULAR LOCATION: CHLOROPLAST.	
DR	Hydrolase; Glycosidase; Carbohydrate metabolism; Seed; Germination; Calcium; Multigene family.	CC CC -!- TISSUE SPECIFICITY: EXPRESSED IN ALL PLANT TISSUES.	
KW		CC CC -!- MISCELLANEOUS: ON THE 2D-GEL ITS MW IS: 16.5 KDa.	
FT	NON_TER 5	DR InterPro; IPRO0179; Ribosomal_L10.	
SQ	SEQUENCE 5 AA: 600 MW;	DR InterPro; IPRO02363; Ribosomal_L10.	
Query Match	0.0%	DR PF00466; Ribosomal_L10; PARTIAL.	
Best Local Similarity	0.0%	DR PROSITE; PS01109; RIBOSOMAL_L10; PARTIAL.	
Matches	0;	KW Ribosomal protein; Chloroplast; rRNA-binding.	
QY	1 X 1	FT NON_TER 6 AA: 675 MW;	6321B415B05DB000 CRC64;
Db	2 A 2	SQ Sequence 6 AA: 675 MW;	6321B415B05DB000 CRC64;
RESULT 4			
ID	P83308	PRELIMINARY;	PRT;
AC	P83308;	5 AA.	
DT	01-JUN-2002 (TREMBLrel. 21, Created)		
DT	01-JUN-2002 (TREMBLrel. 21, Last sequence update)		
DT	01-JUN-2002 (TREMBLrel. 21, Last annotation update)		
DE	FMRFamide-like neuropeptide (LPRLF-anide).		
OS	Galulus gallus (Chicken).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauvia; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.		
OC	NCBI_TaxID=9031;	OX	
RN		RN [1]	
RP		RP	
SEQUENCE		SEQUENCE, AND SYNTHESIS.	
RC	STRAIN=BRAIN;	RC TISSUE=BRAIN;	
RA	Submitted (JUL-2001) to the SWISS-PRON data bank.	RA Pubmed=6137771;	
FT	"A novel active pentapeptide from chicken brain identified by antibodies to FMRFamide.";	FT RT	
RT	"A novel active pentapeptide from chicken brain identified by antibodies to FMRFamide.";	RT RL	
RA	Dockray G.J., Reeve J.R. Jr., Shively J., Gayton R.J., Barnard C.S.;	RA CC -!- FUNCTION: MAY FUNCTION AS A NEUROTRANSMITTER OR MODULATOR.	
RA	"A novel active pentapeptide from chicken brain identified by antibodies to FMRFamide.";	RA CC -!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE) FAMILY.	
RA	Nature 305:328-330(1993).	RA KW Neuropeptide.	
RA	CC -!- SIMILARITY: BELONGS TO THE FARP (FMRFAMIDE RELATED PEPTIDE) FAMILY.	RA SQ Sequence 5 AA: 645 MW;	69d4073767400000 CRC64;
Query Match	0.0%	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 1; Indels 0; Gaps 0;	
Best Local Similarity	0.0%	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Conservative 0; Matches 0; Score 0; DB 13; Length 5;	
Matches	0;	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Conservative 0; Matches 0; Score 0; DB 13; Length 5;	
QY	1 X 1	QY 1 X 1	
Db	1 L 1	Db 1 L 1	
RESULT 5			
ID	P82181	PRELIMINARY;	PRT;
AC	P82181;	6 AA.	
DT	01-JUN-2000 (TREMBLrel. 14, Created)		
DT	01-JUN-2000 (TREMBLrel. 14, Last sequence update)		
DT	01-MAR-2002 (TREMBLrel. 20, Last annotation update)		
DE	Chloroplast 50S ribosomal protein L10 beta (Fragment).		
OS	Spinacia olaracea (Spinach).		
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
OC	Spermatophytina; Magnoliophyta; eudicotyledons; core eudicots;		
OC	Caryophyllidae; Caryophyllales; Chenopodiaceae; Spinacia.		
OX	NCBI_TaxID=5562;	OX	
RN		RN [1]	
RP		RP	
SEQUENCE		SEQUENCE, ALWARO; TISSUE=LEAF;	
RC	STRAIN=CV. ALWARO; TISSUE=LEAF;	RC MEDLINE=20435798; PubMed=10874046;	
RX		RC Yamaguchi K., Subramanian A.R.;	
RA		RA "The plastid ribosomal proteins. Identification of all the proteins in the 50 S subunit of an organelle ribosome (chloroplast).";	
RT		RT RL J. Biol. Chem. 275:2846-2848(2000).	
RT		RT CC -!- FUNCTION: THIS PROTEIN BINDS DIRECTLY TO 23S RIBOSOMAL RNA.	
RT		RT CC -!- SUBCELLULAR LOCATION: CHLOROPLAST.	
RT		RT CC -!- TISSUE SPECIFICITY: EXPRESSED IN ALL PLANT TISSUES.	
CC		RT CC -!- MISCELLANEOUS: ON THE 2D-GEL ITS MW IS: 16.5 KDa.	
CC		RT DR InterPro; IPRO0179; Ribosomal_L10.	
CC		RT DR InterPro; IPRO02363; Ribosomal_L10.	
CC		RT DR PF00466; Ribosomal_L10; PARTIAL.	
CC		RT DR PROSITE; PS01109; RIBOSOMAL_L10; PARTIAL.	
CC		RT KW Ribosomal protein; Chloroplast; rRNA-binding.	
FT	NON_TER 6 AA: 675 MW;	FT NON_TER 6 AA: 675 MW;	6321B415B05DB000 CRC64;
SQ	SEQUENCE 6 AA: 675 MW;	SQ Sequence 6 AA: 675 MW;	6321B415B05DB000 CRC64;
Query Match	0.0%	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 1; Indels 0; Gaps 0;	
Best Local Similarity	0.0%	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Conservative 0; Matches 0; Score 0; DB 10; Length 5;	
Matches	0;	Query Match Best Local Similarity 0.0%; Pred. No. 0; Mismatches 0; Conservative 0; Matches 0; Score 0; DB 10; Length 5;	
QY	1 X 1	QY 1 X 1	
Db	2 A 2	Db 2 A 2	

Best Local Similarity 0.0%; Pred. No. 0;
Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
RN [1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
RC STRAIN=CV_ALVARO; TISSUE=LEAF;
RX MEDLINE=20435797; PubMed=1084039;
RA Yamauchi K., von Knoblauch K., Subramanian A.R.;
RT "The plastid ribosomal proteins. Identification of all the proteins in
the small subunit of an organelle ribosome (chloroplast).";
RL J. Biol. Chem. 37:28455-28465(2000).
CC -!- FUNCTION: THIS PROTEIN BINDS DIRECTLY TO 16S RIBOSOMAL RNA.
CC -!- SUBCELLULAR LOCATION: CHLOROPLAST.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN ALL PLANT TISSUES.
CC -!- MASS SPECTROMETRY: MW=10477.0; METHOD=ELECTROSPRAY.
CC -!- MASS SPECTROMETRY: MW=10495.0; METHOD=MALDI.
CC -!- MISCELLANEOUS: S19 ALPHABET AND BETA FORMS DIFFER IN PI. S19 BETA
FORM IS THE MINOR BASIC FORM.
CC -!- MISCELLANEOUS: ON THE 2D-GEL ITS MW IS: 1.2 KDA.
CC -!- MISCELLANEOUS: ON THE S19 FAMILY OF RIBOSOMAL PROTEINS.
DR InterPro:IPR002222; Ribosomal_S19.
DR Pfam:PF00203; Ribosomal_S19; PARTIAL.
DR PR0097; RIBOSOMALS19; PARTIAL.
DR PROSITE; PS00333; RIBOSOMAL_S19; PARTIAL.
KW Ribosomal protein; Chloroplast; rRNA-binding.
NON_TER 6
SEQUENCE 6 AA; 732 MW; 63333375411C000 CRC64;
Q Query Match 0.0%; Score 0; DB 10; Length 6;
Best Local Similarity 0.0%; Pred. No. 0;
Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RA Yamaguchi K., Subramanian A.R.;
RT "The plastid ribosomal proteins. Identification of all the proteins in
the 50 S subunit of an organelle ribosome (chloroplast).";
RL J. Biol. Chem. 275:28466-28482(2000).
CC -!- FUNCTION: THIS PROTEIN BINDS DIRECTLY TO 23S RIBOSOMAL RNA.
CC -!- SUBCELLULAR LOCATION: CHLOROPLAST.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN ALL PLANT TISSUES.
CC -!- MISCELLANEOUS: ON THE 2D-GEL ITS MW IS: 16.5 KDA.
CC -!- MISCELLANEOUS: BELONGS TO THE L10 FAMILY OF RIBOSOMAL PROTEINS.
DR InterPro:IPR011790; Ribosomal_L10.
DR InterPro:IPR023633; Ribosomal_L10sub.
AC P00466; Ribosomal_L10; PARTIAL.
PFam:PF00466; Ribosomal_L10; PARTIAL.
PROSITE; PS01109; RIBOSOMAL_L10; PARTIAL.
KW Ribosomal protein; Chloroplast; rRNA-binding.
NON_TER 6
SEQUENCE 6 AA; 675 MW; 6321B415B05DB000 CRC64;
Q Query Match 0.0%; Score 0; DB 10; Length 6;
Best Local Similarity 0.0%; Pred. No. 0;
Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 1 A 1

RESULT 6
P82541 PRELIMINARY; PRT; 6 AA.
ID P82541;
AC P02541;
DT 01-OCT-2000 (TREMBLrel. 15, Created)
DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)
DT 01-JUN-2001 (TREMBLrel. 17, Last annotation update)
DE Chloroplast 30S ribosomal protein S19 beta (Fragment).
S Chloroplast.
S Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
S Spermatophyta; Magnoliophyta; euodiatelyoids; core eudicots;
S Caryophyllidae; Caryophyllales; Chenopodiaceae; Spinacia.
OC NCBI_TAXID=3562;
OX [1]
RN [1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
RC STRAIN=CV_ALVARO; TISSUE=LEAF;
RX MEDLINE=20435797; PubMed=1084039;
RA Yamauchi K., von Knoblauch K., Subramanian A.R.;
RT "The plastid ribosomal proteins. Identification of all the proteins in
the small subunit of an organelle ribosome (chloroplast).";
RL J. Biol. Chem. 37:28455-28465(2000).
CC -!- FUNCTION: THIS PROTEIN BINDS DIRECTLY TO 16S RIBOSOMAL RNA.
CC -!- SUBCELLULAR LOCATION: CHLOROPLAST.
CC -!- TISSUE SPECIFICITY: EXPRESSED IN ALL PLANT TISSUES.
CC -!- MASS SPECTROMETRY: MW=10477.0; METHOD=ELECTROSPRAY.
CC -!- MASS SPECTROMETRY: MW=10495.0; METHOD=MALDI.
CC -!- MISCELLANEOUS: S19 ALPHABET AND BETA FORMS DIFFER IN PI. S19 BETA
FORM IS THE MINOR BASIC FORM.
CC -!- MISCELLANEOUS: ON THE 2D-GEL ITS MW IS: 1.2 KDA.
CC -!- MISCELLANEOUS: ON THE S19 FAMILY OF RIBOSOMAL PROTEINS.
DR InterPro:IPR002222; Ribosomal_S19.
DR Pfam:PF00203; Ribosomal_S19; PARTIAL.
DR PR0097; RIBOSOMALS19; PARTIAL.
DR PROSITE; PS00333; RIBOSOMAL_S19; PARTIAL.
KW Ribosomal protein; Chloroplast; rRNA-binding.
NON_TER 6
SEQUENCE 6 AA; 732 MW; 63333375411C000 CRC64;
Q Query Match 0.0%; Score 0; DB 10; Length 6;
Best Local Similarity 0.0%; Pred. No. 0;
Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 1 T 1

RESULT 7
P82182 PRELIMINARY; PRT; 6 AA.
ID P82182;
AC P02182;
DT 01-JUN-2000 (TREMBLrel. 14, Created)
DT 01-JUN-2000 (TREMBLrel. 14, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Chloroplast 50S ribosomal protein L10 gamma (Fragment).
S Spinacia oleracea (Spinach).
S Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
S Spermatophyta; Magnoliophyta; euodiatelyoids; core eudicots;
S Caryophyllidae; Caryophyllales; Chenopodiaceae; Spinacia.
OC NCBI_TAXID=3562;
OX [1]
RN [1]
RP SEQUENCE.
RC STRAIN=CV_ALVARO; TISSUE=LEAF;
RX MEDLINE=20435797; PubMed=10874046;

RN	[1]	SEQUENCE FROM N.A.	RA	Kim Y.-C.;
RP	MEDLINE=94079349; PubMed=8257126;	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.	RL	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
RX	Rather P.N., Mann P.A., Mierzwa R., Hare R.S., Miller G.H., Shaw K.J.;		DR	EMBL: U88208; AAB66311; 1; -
RA	"Analysis of the aac(3')-VIA gene encoding a novel 3-N-		KW	Dioxygenase.
RT	acetyltransferase.";		FT	NON-TER
RT	Antimicrob Agents Chemother. 37:2074-2079(1993).		SQ	SEQUENCE 7 AA; 868 MW; 71AA52D1A699D460 CRC64;
RL			Query	Match
DR			Best Local Similarity 0.0%;	Score 0; DB 2; Length 7;
DR	EMBL: 088012; AAC1619.1; -.		Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
FT				
NON-TER	1 1			
SQ	SEQUENCE 7 AA; 744 MW; 633862D2C321A030 CRC64;			
Query Match	Best Local Similarity 0.0%;	Score 0; DB 2; Length 7;	Qy	1 X 1
Matches	0; Conservative 0;	Pred. No. 0;	Db	4 T 4
Qy	1 X 1			
Db	2 T 2			
RESULT 10	050556	PRELIMINARY;	PRT;	7 AA.
050556	01-JUN-1998 (TREMBLrel. 06 Created)		Q47477	PRELIMINARY;
050556	01-JUN-1998 (TREMBLrel. 06 Last sequence update)		ID	047477
DT	01-JUN-2001 (TREMBLrel. 17 Last annotation update)		AC	047477
DT	01-JUN-2001 (TREMBLrel. 17 Last annotation update)		DT	01-NOV-1996 (TREMBLrel. 01, Created)
DE	GLyA (Fragment).		DT	01-MAY-1999 (TREMBLrel. 10, Last sequence update)
GN			DE	Tpi protein (Fragment).
OS	Actinobacillus actinomycetemcomitans (Haemophilus		GN	Tpi
OS	actinomycetemcomitans);		OS	Bacteria; Proteobacteria; gamma subdivision: Enterobacteriaceae;
OS	Bacteria; Proteobacteria; gamma subdivision: Pasteurellaceae;		OC	Escherichia coli.
OC	Actinobacillus		OX	Escherichia.
NCBI_TAXID=714;			NCBI_TAXID=562;	
RN			OX	
SEQUENCE FROM N.A.			SEQUENCE FROM N.A.	
RA	Kolodrubetz D., Spitznagel J. Jr., wang B., Phillips L.H., Jacobs C., Kraig E.;		RA	Submitted (OCT-1986) to the EMBL/GenBank/DBJ databases.
RA	"cis Elements and trans factors are both important in strain-specific regulation of the leukotoxin gene in <i>Actinobacillus</i>		RL	SEQUENCE OF 7-7 FROM N.A.
RT	actinomycetemcomitans";		DR	MEDLINE=85203917; PubMed=3158524;
RT	actinomycetemcomitans";		FT	Medline H.W., Evans P.R.;
RT	Infec Immun. 68:3451-3460(1996).		SQ	"Nucleotide sequence and high-level expression of the major
DR	EMBL: U51862; AAC88721.1; -.		RT	Escherichia coli phosphofructokinase.";
DR	U51862; AAC88721.1; -.		RT	Eur. J. Biochem. 149:363-373(1985).
NON-TER	1 1		RN	SEQUENCE FROM N.A.
SQ	SEQUENCE 7 AA; 832 MW; 6DCB42D767340420 CRC64;		RA	Evans P.;
Query Match	Best Local Similarity 0.0%;	Score 0; DB 2; Length 7;	RL	Submitted (OCT-1986) to the EMBL/GenBank/DBJ databases.
Matches	0; Conservative 0;	Pred. No. 0;	DR	MEDLINE=X02519; CAA26359.1; -.
Qy	1 X 1		FT	NON-TER
Db	7 A 7		SQ	SEQUENCE 7 AA; 773 MW; 7416D33DDDB1D80 CRC64;
RESULT 11	034028	PRELIMINARY;	PRT;	7 AA.
034028	01-JAN-1998 (TREMBLrel. 05 Created)		Q47505	PRELIMINARY;
034028	01-JAN-1998 (TREMBLrel. 05 Last sequence update)		ID	047505
DT	01-DEC-2001 (TREMBLrel. 19 Last annotation update)		AC	047505
DT	Catechol-2,3-dioxygenase (Fragment).		DT	01-NOV-1996 (TREMBLrel. 01, Created)
DE	PHNE.		DT	01-NOV-1996 (TREMBLrel. 01, Last sequence update)
GN			DE	01-DEC-2001 (TREMBLrel. 19, Last annotation update)
OS	Sphingomonas chungbukensis		GN	MCCA.
OC	Bacteria; Proteobacteria; alpha subdivision: Sphingomonadaceae;		OG	Plasmid pMCC07.
OC	Sphingomonas.		OS	Escherichia coli.
NCBI_TAXID=56193;			OC	Bacteria; Proteobacteria; gamma subdivision: Enterobacteriaceae;
RN			OC	Escherichia.
RP	SEQUENCE FROM N.A.		OX	NCBI_TAXID=562;
RC	SEQUENCE STRAIN=DJ77;		RP	SEQUENCE FROM N.A.
			RX	MEDLINE=96099297; PubMed=8322520;
			RA	Gonzalez-Pastor J.E., San Millan J.L., Castilla M.A., Moreno F.;
			RT	"Structure and organization of plasmid genes required to produce the
			RT	translational inhibitor microcin C7."

RL J. Bacteriol. 177:7131-7140(1995).
 KW EMBL; X57583; CAA40808.1; -.
 SQ SEQUENCE 7 AA; 763 MW; 644DD44861B406F0 CRC64;

Query Match	Score 0;	DB 2;	Length 7;
Best Local Similarity	0.0%	Pred. No 0;	Score 0;
Matches 0;	Conservative 0;	Mismatches 0;	Indels 0;
Qy 1 X 1	Db 3 T 3	Qy 1 X 1	Db 2 T 2

Search completed: February 12, 2003, 11:46:58
 Job time : 61.2667 secs

RESULT 14

P70804 ID P70804 PRELIMINARY; PRT; 7 AA.
 IC P70804; 01-FEB-1997 (TREMBLrel. 02, Created)
 DT 01-NOV-1997 (TREMBLrel. 02, Last sequence update)
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
 DE AlgT protein (Fragment).
 GN ALGT.
 OS Azotobacter vinelandii.
 OC Bacteria; Proteobacteria; gamma subdivision; pseudomonadaceae;
 OC Azotobacter.
 OX NCBI_TAXID=54;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=N.E;
 RX MEDLINE=96427318; PubMed=8830682;
 RA Rehman, B.H.A., Ertesvag H., Valla S.;
 RT "A new Azotobacter vinelandii mannuronan C-5-epimerase gene (algG) is
 part of an alg gene cluster physically organized in a manner similar
 to that in *Pseudomonas aeruginosa*."
 RT J. Bacteriol. 178:5884-5889(1996).
 DR EMBL; X87973; CAA61230.1;
 FT NON-TER 1 1
 SQ SEQUENCE 7 AA; 684 MW; 71B5A5A2D1AED0 CRC64;

Query Match	Score 0;	DB 2;	Length 7;
Best Local Similarity	0.0%	Pred. No 0;	Score 0;
Matches 0;	Conservative 0;	Mismatches 0;	Indels 0;
Qy 1 X 1	Db 2 T 2	Qy 1 X 1	Db 2 T 2

RESULT 15

Q54248 ID Q54248 PRELIMINARY; PRT; 7 AA.
 AC Q54248;
 DT 01-NOV-1996 (TREMBLrel. 01, Created)
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
 DE RplO protein (Fragment).
 GN RplO.
 OS Streptomyces griseus.
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
 OC Actinomycetales; Streptomycineae; Streptomyctaceae; Streptomyces.
 OX NCBI_TAXID=1911;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Q2-3-11;
 RX MEDLINE=20011291; PubMed=10542330;
 RA Poehling S., Piepersberg W., Weimer U.F.;
 RT "Analysis and regulation of the secY gene from *Streptomyces griseus*
 N2-3-11 and interaction of the SECY protein with the SecA protein.";
 RL Biochim. Biophys. Acta 1447:298-302(1999).
 DR X95915; CAA65160.1; -.
 FT NON-TER 1 1
 SQ SEQUENCE 7 AA; 760 MW; 72C72B01B2D1B2A0 CRC64;

THIS PAGE BLANK (USPTO).

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compigen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2003, 11:39:30 ; Search time 28 Seconds
(without alignments)
33.313 Million cell updates/sec

Title: US-09-660-302c-7
Perfect score: 43
Sequence: 1 CEEDFYR 7

Scoring table: BLOSUM62
Gapext 0.5
Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002: *
1: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1980.DAT: *
2: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1981.DAT: *
3: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1982.DAT: *
4: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1983.DAT: *
5: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1984.DAT: *
6: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1985.DAT: *
7: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1986.DAT: *
8: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1987.DAT: *
9: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1988.DAT: *
10: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1989.DAT: *
11: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1990.DAT: *
12: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1991.DAT: *
13: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1992.DAT: *
14: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1993.DAT: *
15: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1994.DAT: *
16: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1995.DAT: *
17: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1996.DAT: *
18: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1997.DAT: *
19: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1998.DAT: *
20: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1999.DAT: *
21: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2000.DAT: *
22: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2001.DAT: *
23: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2002.DAT: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	43	100.0	7	20	AAY32791	Proteolytic cleavage
2	38	88.4	33	13	AAR2456	Plasmid pRSR8-3 en
3	38	88.4	246	15	AAR56389	Human growth horno
4	38	88.4	249	11	AAR06867	Hormone binding re
5	38	88.4	269	11	AAR05045	Soluble human grow
6	38	88.4	269	18	AAW10426	Human somatogenic
7	38	88.4	269	20	AAY31767	Human soluble grow
8	38	88.4	269	20	AAW82802	Human soluble soma
9	38	88.4	269	21	AAY78429	Soluble part of the
10	38	88.4	315	23	AAU75429	Human fusion prote

11	38	88.4	340	23	AU75496	Human fusion prote
12	38	88.4	637	10	APP92108	Human growth horno
13	38	88.4	638	9	AAB81326	Human growth horno
14	38	88.4	638	19	AWM33394	Human growth horno
15	38	88.4	648	22	ABB11437	Mature nematode ex
16	36	83.7	84	20	AAY30432	A. caninum nematod
17	36	83.7	94	21	ABB15317	Acanthocystis t
18	36	83.7	91	17	ABR91701	Ancylosoma leucogramma
19	36	83.7	91	20	AAY30393	Nematode, extracted
20	36	83.7	91	20	AAY30454	Nematode, extracted
21	36	83.7	91	21	AAB15346	A. caninum nematod
22	36	83.7	404	19	AWM54077	LH-2 Protein #1
23	36	83.7	406	22	ABW95251	Human protein sequ
24	36	83.7	423	19	AQW54078	LH-2 Protein #2
25	34	79.1	49	22	AQW11680	Human polypeptide
26	34	79.1	102	23	ABP30709	Streptococcus poly
27	34	79.1	615	22	ABG07365	Novel human diagno
28	34	79.1	1589	22	AUW00294	Interferon induced
29	34	79.1	1591	22	ABR32113	Peptide #4764 enco
30	34	79.1	1591	22	ABW05938	Peptide #4871 enco
31	34	79.1	1591	22	ABW22654	Human peptide enco
32	34	79.1	1591	22	AMW58054	Human brain expres
33	34	79.1	1591	22	AMW70495	Human bone marrow
34	34	79.1	1591	22	AMW18331	Peptide #4765 enco
35	34	79.1	1591	22	AMW30819	Peptide #4856 enco
36	34	79.1	1591	22	AMW40136	Human peptide enco
37	34	79.1	1591	22	AMW4014	Mature nematode ex
38	33	76.7	75	20	AAY30414	Mature nematode ex
39	33	76.7	77	20	AAY30431	Mature nematode ex
40	33	76.7	78	20	AAY30420	Mature nematode ex
41	33	76.7	78	21	ABB15305	A. caninum nematod
42	33	76.7	82	20	AAY30399	Nematode, extracted
43	33	76.7	82	20	AAY30422	Mature nematode ex
44	33	76.7	82	21	ABB15293	A. ceylanicum nema
45	33	76.7	82	21	ABB15307	A. ceylanicum nema

ALIGNMENTS

RESULT 1	AYA32791	standard; peptide: 7 AA.
ID	AYA32791	(first entry)
XX		Proteolytic cleavage signal site used in inhibiting receptor proteolysis.
AC	AAY32791;	Signal transduction; Proteolytic cleavage; cleavage signal site;
XX		ubiquitin; proteosome binding site; muscle wasting; renal tubular defect; uraemia; diabetes; cushing's disease; eating disorder; AIDS; growth hormone deficiency.
XX	OS	Mammalia.
XX	PN	EP943624-A1.
XX	PD	22-SEP-1999.
XX	PF	12-MAR-1998;
XX	PR	12-MAR-1998;
XX	XX	98EP-0200799.

Copyright (c) 1993 - 2003 Compigen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2003, 11:39:30 ; Search time 28 Seconds
(without alignments)
33.313 Million cell updates/sec

XX

Title: US-09-660-302c-7

XX

Perfect score: 43

XX

Sequence: 1 CEEDFYR 7

XX

Scoring table: BLOSUM62

XX

Gapext 0.5

XX

Searched: 908470 seqs, 133250620 residues

XX

Total number of hits satisfying chosen parameters: 908470

XX

Minimum DB seq length: 0

XX

Maximum DB seq length: 2000000000

XX

Post-processing: Minimum Match 0%

XX

Maximum Match 100%

XX

Listing first 45 summaries

XX

Database : A_Geneseq_101002: *

XX

1: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1980.DAT: *

XX

2: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1981.DAT: *

XX

3: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1982.DAT: *

XX

4: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1983.DAT: *

XX

5: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1984.DAT: *

XX

6: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1985.DAT: *

XX

7: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1986.DAT: *

XX

8: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1987.DAT: *

XX

9: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1988.DAT: *

XX

10: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1989.DAT: *

XX

11: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1990.DAT: *

XX

12: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1991.DAT: *

XX

13: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1992.DAT: *

XX

14: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1993.DAT: *

XX

15: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1994.DAT: *

XX

16: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1995.DAT: *

XX

17: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1996.DAT: *

XX

18: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1997.DAT: *

XX

19: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1998.DAT: *

XX

20: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1999.DAT: *

XX

21: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2000.DAT: *

XX

22: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2001.DAT: *

XX

23: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2002.DAT: *

XX

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

XX

SUMMARIES

XX

1: 43 100.0 7 20 AAY32791

XX

2: 38 88.4 33 13 AAR2456

XX

3: 38 88.4 246 15 AAR56389

XX

4: 38 88.4 249 11 AAR06867

XX

5: 38 88.4 269 11 AAR05045

XX

6: 38 88.4 269 18 AAW10426

XX

7: 38 88.4 269 20 AAY31767

XX

8: 38 88.4 269 20 AAW82802

XX

9: 38 88.4 269 21 AAY78429

XX

10: 38 88.4 315 23 AAU75429

XX

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

XX

Result No.

XX

Score

XX

Query Match

XX

Length

XX

DB

XX

ID

XX

Description

XX

Protolytic cleavage

XX

Plasmid pRSR8-3 en

XX

Human growth horno

XX

Hormone binding re

XX

Soluble human grow

XX

Human somatogenic

XX

Human soluble grow

XX

Human soluble soma

XX

Soluble part of the

XX

Human fusion prote

XX

PS	Claim 15; Page 27;	36pp;	English.	0;	Gaps
XX	This sequence is a cleavage signal site. This site is used in a method for controlling the availability and signal transduction capability of a cell surface receptor by administering an inhibitor that is capable of inhibiting proteolytic cleavage of the receptor. Inhibition of this proteolytic cleavage results in the receptors being present on the surface for longer and therefore signalling for longer to the interior of the cell. This increases the sensitivity of cells to any hormones which might be present. The inhibitor is derived from or competes with an amino acid sequence around this proteolytic cleavage signal. The inhibitor may be used to treat muscle wasting, associated with disorders such as renal tubular defects, uraemia, diabetes, Cushing's syndrome, cachexias, eating disorders, AIDS, after stress and during neuromuscular disease.	XX	XX	XX	XX
XX	Sequence 7 AA;	Query Match 1 CEEDEFY 7	Score 43; DB 20; Length 7; Best Local Similarity 100.0%; Pred. No. 7.8e+05; Mismatches 0; Indels 0; Gaps 0;	XX	XX
XX	1 CEEDEFY 7	1 CEEDEFY 7	XX	XX	XX
XX	RESULT 2 AAR22456	ID AAR22456 standard; Protein: 33 AA.	XX	XX	XX
XX	AC AAR22456;	XX	XX	XX	XX
XX	09-SEP-1992 (first entry)	XX	XX	XX	XX
XX	Plasmid pESR8-3 encoded polypeptide.	XX	XX	XX	XX
XX	Recombinant plasmid pACYMhGHR; hGHR binding region; human growth hormone.	XX	XX	XX	XX
XX	Synthetic.	XX	XX	XX	XX
XX	JP01063594-A.	XX	XX	XX	XX
XX	PD 28-FEB-1992.	XX	XX	XX	XX
XX	03-JUL-1990; 90JP-0176630.	XX	XX	XX	XX
XX	03-JUL-1990; 90JP-0176630.	XX	XX	XX	XX
XX	PA (TANP-) TANPAKU KAGAKU KENK.	XX	XX	XX	XX
XX	WPI; 1992-120154/15.	XX	XX	XX	XX
XX	N-PADB; ANQ23311.	XX	XX	XX	XX
XX	New recombinant plasmid and Baculovirus having specific DNA fragment - used for prepn. of hormone binding region protein of human growth hormone receptor.	XX	XX	XX	XX
XX	Example; Fig 2; 11pp; Japanese.	XX	XX	XX	XX
XX	The sequence is that encoded by a fragment of the plasmid pBSR8-3 which is used in the construction of the plasmid pACTMhGHR. pACTMhGHR contains a DNA fragment encoding the binding region of human growth hormone receptor (hGHR) under control of a Baculovirus gene expression system. This can be used to transform insect cells to produce a more natural protein than is obtnd. with E.coli and in larger amts. See also AAR22457-R22459.	XX	XX	XX	XX
XX	Sequence 33 AA;	Query Match 1 CEEDEFY 6	Score 38; DB 13; Length 33; Best Local Similarity 100.0%; Pred. No. 1.9;	XX	XX
XX	1 CEEDEFY 6	1 CEEDEFY 6	XX	XX	XX
XX	RESULT 3 AAR56389	ID AAR56389 standard; protein: 246 AA.	XX	XX	XX
XX	AC AAR56389;	XX	XX	XX	XX
XX	01-MAR-1995 (first entry)	XX	XX	XX	XX
XX	DE Human growth hormone receptor C-domain.	XX	XX	XX	XX
XX	KW Human growth hormone receptor; hGHR; C-domain; CD; hGHR-CD; extracellular; enhancement; Met130Q-238Q; GS129V-238Q.	XX	XX	XX	XX
XX	OS Homo sapiens.	OS	OS	OS	OS
XX	JP06172394-A.	XX	XX	XX	XX
XX	PD 21-JUN-1994.	XX	XX	XX	XX
XX	PF 10-DEC-1992;	XX	XX	XX	XX
XX	PR 10-DEC-1992;	XX	XX	XX	XX
XX	PA (TANP-) TANPAKU KOGAKU KENKYUSHO KK.	XX	XX	XX	XX
XX	WPI; 1994-238767/29.	XX	XX	XX	XX
XX	PT Extracellular C-domain protein of growth hormone receptor (hGHR-CD) - is used to enhance growth hormone function Disclosure; Page 9-10; 16pp; Japanese.	PT	PT	PT	PT
XX	PS CC The extracellular C-domain of hGHR is used to enhance growth hormone function. Two forms, Met130Q-238Q (AQ66550) and GS129V-238Q (AA066553) are given. Primers for the isolation of extracellular hGHR-CD are given in AAQ66551-52 and AAQ66554-55.	PS	PS	PS	PS
XX	XX Sequence 246 AA;	XX	XX	XX	XX
XX	Query Match 1 CEEDEFY 6	Score 38; DB 15; Length 246; Best Local Similarity 100.0%; Pred. No. 14; Mismatches 0; Indels 0; Gaps 0;	XX	XX	XX
XX	DB 241 CEEDEFY 246	XX	XX	XX	XX
XX	RESULT 4 AAR06867	ID AAR06867 standard; protein: 249 AA.	XX	XX	XX
XX	AC AAR06867;	XX	XX	XX	XX
XX	DT 16-JAN-1991 (first entry)	XX	XX	XX	XX
XX	DE Hormone binding region of human growth hormone receptor.	XX	XX	XX	XX
XX	OS Synthetic.	OS	OS	OS	OS
XX	KW hGHR.	KW	KW	KW	KW
XX	XX Sequence 33 AA;	XX	XX	XX	XX
XX	Query Match 1 CEEDEFY 6	Score 38; DB 13; Length 33; Best Local Similarity 100.0%; Pred. No. 1.9;	XX	XX	XX
XX	1 CEEDEFY 6	1 CEEDEFY 6	XX	XX	XX
XX	RESULT 5 AAR2200186-A.	ID AAR2200186-A.	XX	XX	XX
XX	PD 08-AUG-1990.	XX	XX	XX	XX

Matches	6;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;	Qy	1 CEEDEFY 6
Qy	1	CEEDEFY 6								Db	264 CEEDEFY 269
Db	264	CEEDEFY	269								
RESULT 7											
ID	AAY31767	standard;	Protein;	269	AA.						
XX										XX	
AC	AAY31767;									AC	
XX										XX	
DT	06-DEC-1999	(first entry)								DT	01-MAR-1999 (first entry)
XX										XX	
DE	Human soluble growth hormone receptor.									DE	Human soluble somatotrophic receptor.
XX										XX	
KW	Growth hormone receptor; somatotrophic receptor; human; pJ1446;									KW	Somatotrophic receptor; growth hormone; human; plasmid pJ1446;
XX										XX	
KW	variant; protein engineering.									XX	active domain.
OS	Homo sapiens.									OS	Homo sapiens.
XX										XX	
Key		Location/Qualifiers								Key	Location/Qualifiers
Peptide		1..23								FT	1..23
XX		/note= "Signal peptide"								FT	/label= sig-peptide
Protein										FT	24..269
FT		/note= "mature protein"								FT	/label= Mat_protein
FT										PN	US5834250-A.
XX										XX	
PN	US5955346-A.									PD	10-NOV-1998.
XX										XX	
PD	21-SEP-1999.									PF	30-JUN-1997;
XX										PR	26-OCT-1989;
PF	07-JUN-1995;									PR	28-OCT-1988;
XX										PR	27-APR-1992;
PR	02-FEB-1994;									PR	27-APR-1992;
PR	26-OCT-1989;									PR	13-OCT-1992;
PR	27-APR-1992;									PR	02-FEB-1994;
PR	13-OCT-1992;									PR	06-JUN-1995;
PR	13-OCT-1992;									PR	30-JUN-1997;
PR	28-OCT-1988;									XX	
XX										PA	(GETH) GENENTECH INC.
PA										XX	
PA										PA	
PA										XX	
XX										PI	Cunningham BC, Wells JA;
PI										XX	
XX										DR	WPI: 1999-008714/01.
DR	WPI: 1999-008714/01.									DR	N-PSDB; AAV62766.
XX										XX	
XX										PS	Example 3: Fig 12A-J; 84pp; English.
PT	Isolated nucleic acids encoding variants of human prolactin and									XX	
PT	placental lactogen useful for identifying active domains within those									XX	
PT	proteins -									CC	This sequence represents a human soluble growth hormone receptor
CC	(sGHR) encoded by plasmid pJ1446 (see AAY87977). sGHR was									CC	CC
CC	expressed in E. coli and was used in binding assays of human growth									CC	CC
CC	hormone variants. The invention provides a method for the									CC	CC
CC	systematic analysis of the structure and function of polypeptides									CC	CC
CC	by identifying active domains which influence the activity of the									CC	CC
CC	polypeptide with a target substance, and a method for identifying									CC	CC
CC	the active amino acid residues within the active domain of a									CC	CC
CC	polypeptide. It also provides polypeptide variants comprising									CC	CC
CC	segment-substituted and residue-substituted growth hormones,									CC	CC
CC	prolactins (see AAY31764) and placental lactogens (see AAY31765).									CC	CC
CC	Identifying receptor binding sites in hormones permits the rational									CC	CC
CC	design of receptor specific variants.									CC	CC
CC	Sequence 269 AA;									CC	CC
CC	Query Match 68.4%									CC	CC
CC	Best Local Similarity 100.0%									CC	CC
CC	Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									CC	CC

XX SQ Sequence 269 AA;
 Query Match 88.4%; Score 38; DB 20; Length 269;
 Best Local Similarity 100.0%; Pred. No. 16;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CEEDFY 6
 Db 264 CEEDFY 269

RESULT 9
 AAY78429 standard; Protein: 269 AA.
 ID AAY78429
 AC AAU75499;
 XX
 XX 09-MAY-2000 (first entry)
 DT
 DE Soluble part of the somatogenic receptor encoded by plasmid pJ1446.
 XX Human growth hormone; hGH; prolactin; placental lactogen;
 KW modification; mutagenesis.
 XX Homo sapiens.
 OS Synthetic.
 XX
 PN US6013478-A.
 XX
 PD 11-JAN-2000.
 XX
 PF 24-JUN-1998;
 XX 98US-0104036.
 XX
 PR 26-OCT-1989;
 PR 98US-0428066.
 PR 27-APR-1992;
 PR 92US-0875204.
 PR 13-OCT-1992;
 PR 92US-0960227.
 PR 02-FEB-1994;
 PR 94US-0190223.
 PR 06-JUN-1995;
 PR 95US-0483039.
 PR 30-JUN-1995;
 PR 97US-0903398.
 PR 28-OCT-1988;
 PR 88US-0264611.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Wells JA, Cunningham BC;
 XX
 DR WPI; 2000-159873/14.
 DR N-PSDB; AAZ88448.
 XX
 PT Recombinant production of variant polypeptides, e.g. growth hormone variants with altered receptor specificity, using cells transformed with DNA selected by scanning mutagenesis in at least one peptide domain.
 PT
 XX
 PS Example 3; Fig 12; 83pp; English.
 XX
 CC The present invention describes the production of a polypeptide variant (I) comprising segment substituted and residue substituted growth hormone, prolactin or placental lactogen. The method is particularly used to produce variants of growth hormone (GH), prolactin or placental lactogen, but may also be applied to receptors, interferons, and colony-stimulating factors. A particular application is the production of human GH variants with altered (decreased or increased) binding interaction with the somatogenic receptor, i.e. compounds useful as human GH (ant)agonists and which may have higher potency for stimulating other human GH receptors, and as standards or tracers in immunoassays for human GH. This method of DNA selection identifies the biologically active residues in active domains, including those critical for interaction with different targets. The present sequence represents the soluble region of the somatogenic receptor from liver encoded by a plasmid, which is used in the exemplification of the present invention.
 XX Sequence 269 AA;

Query Match 88.4%; Score 38; DB 21; Length 269;
 Best Local Similarity 100.0%; Pred. No. 16;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CEEDFY 6
 Db 264 CEEDFY 269

RESULT 10
 AAU75499
 ID AAU75499 standard; Protein: 315 AA.
 AC AAU75499;
 XX
 XX 08-MAY-2002 (first entry)
 DT
 DE Human fusion protein Chi 1A2.
 XX
 KW Human; GHS1-23; human growth hormone; GH; GHR; growth hormone; receptor; GhstopGHR SD100; GhlinkGHR; GhlinkGHRflec; patrCNSSAC; TrcHindar; Chi 1A2 chimaera; acromegaly; gigantism; growth hormone deficiency; Turner's syndrome; renal failure; osteoporosis; diabetes mellitus; cancer; obesity; insulin resistance; hyperlipidaemia; hypertension; anaemia; autoimmune disease; infectious disease; inflammatory disorder; rheumatoid arthritis; interleukin-6 chimaera; IL-6.
 KW
 XX Homo sapiens.
 OS
 XX
 FH Key
 FH Misc-difference 14
 FT /note= "Encoded by ATG"
 FT
 FT Misc-difference 312
 FT /label= Unknown
 FT
 FT Misc-difference 313
 FT /note= "Encoded by TGA, in-frame stop codon"
 FT
 FT Misc-difference 313
 FT /label= Unknown
 FT
 FT /note= "Encoded by TAA, in-frame stop codon"
 XX
 PN WO200196565-A2.
 XX
 PD 20-DEC-2001.
 XX
 PP 18-JUN-2001; 2001WO-GB02645.
 XX
 PR 16-JUN-2000; 2000GB-0014765.
 PR 10-MAR-2001; 2001GB-0005669.
 PR 16-MAR-2001; 2001GB-0006487.
 XX
 PA (ASTE) ASTERION LTD.
 XX
 PI Ross R, Artymuk P, Sayers J;
 XX
 DR WPI; 2002-130734/17.
 DR N-PSDB; ABR14547.
 XX
 PS Claim 49; Fig 22; 79pp; English.
 XX
 CC The invention relates to a binding agent comprising a first part capable of binding ligand binding domain of a receptor linked to a second part comprising a receptor binding domain, where the binding agent modulates the activity of the receptor. Also included are a nucleic acid molecule having a sequence, which encodes a binding agent comprising sequences given in the specification, which sequences represent the sequences of the full length GhstopGHR SD100 construct, GhlinkGHR construct(GH, growth hormone, GHR, growth hormone receptor), GhlinkGHRflec construct, 1157 base pair

PCR fragment GHlinkGHR generated by nucleotides pTCRNSsaci and Trchindrev, or the nucleotide sequence of the Chi 1A2 chimaera, sequences binding to the nucleic acids or degenerate sequences, representing them (which have receptor antagonising activity), their encoded polypeptides, a vector comprising the nucleic acids and a cell transformed/transfected with the nucleic acid or vector. The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera). The present sequence represents the fusion protein agent of the invention being the Chi 1A2 construct (growth hormone/growth hormone receptor not linked by a synthetic peptide linker).

Sequence 315 AA;
 Query Match 88.4%; Score 38; DB 23; Length 315;
 Best Local Similarity 100.0%; Pred. No. 18;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC 1 CEEDDFY 6
 CC 11111
 DB 306 CEEDDFY 311

RESULT 11
 AAU75496 Standard; Protein: 340 AA.
 XX
 AC AAU75496;
 DT 08-MAY-2002 (first entry)

XX
 DE Human fusion protein GHlinkGHR.
 XX Human; GHs1-23; Human growth hormone; GH; GHR;
 KW growth hormone; receptor; GHstopGHR SD100; GHlinkGHRflec;
 KW pTCRNSsaci; Trchindrev; Chi 1A2 chimaera; acromegaly; gigantism;
 KW growth hormone deficiency; Turner's syndrome; renal failure;
 KW osteoporosis; diabetes mellitus; cancer; obesity; insulin resistance;
 KW hyperlipidaemia; hypertension; anaemia; autoimmune disease;
 KW infectious disease; inflammatory disorder; rheumatoid arthritis;
 KW interleukin-6 chimaera; IL-6.

XX
 OS Homo sapiens.
 OS Synthetic.

XX
 FH Key
 FH Misc-difference 14

Location/Qualifiers
 Misc-difference 337
 /note= "Encoded by ATG"

FT /Label= Unknown
 FT /note= "Encoded by tGA, in-frame stop codon"
 FT Misc-difference 338
 /Label= Unknown
 /note= "Encoded by tAA, in-frame stop codon"

XX
 WO200106565-A2.
 PN 20-DEC-2001.

XX
 18-JUN-2001; 2001WO-GB02645.

XX
 PD 20-DEC-2001.
 XX
 PR 16-JUN-2000; 2000GB-0014765.
 PR 10-MAR-2001; 2001GB-0005969.
 PR 16-MAR-2001; 2001GB-0006487.

XX
 PA (ASTE-) ASTERION LTD.

XX
 PI Ross R, Artymiuik P, Sayers J;

WPI: 2002-130734/17.
 DR N-PSDB; ABK14531.

XX
 PT New binding agent useful in producing a medicament for treating e.g. cancer, obesity, acromegaly or gigantism, comprises a first part that binds to a ligand binding domain of a receptor and a second part having a receptor binding domain -

XX Disclosure; Fig 6: 79PP: English.

XX The invention relates to a binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a second part comprising a receptor binding domain, where the binding agent modulates the activity of the receptor. Also included are a nucleic acid molecule having a sequence, which encodes a binding agent comprising sequences given in the specification comprising the sequences of the full length

CC GHstopGHR SD100 construct, GHlinkGHRflec construct, 1157 base pair

CC PCR fragment GHlinkGHR generated by nucleotides pTCRNSsaci and

CC Trchindrev, or the nucleotide sequence of the Chi 1A2 chimaera, sequences binding to the nucleic acids or degenerate sequences

CC representing them (which have receptor antagonising activity), their encoded polypeptides, a vector comprising the nucleic acid and a

CC cell transformed/transfected with the nucleic acid or vector.

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

XX Sequence 340 AA;

Query Match 88.4%; Score 38; DB 23; Length 340;

Best Local Similarity 100.0%; Pred. No. 20;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The binding agent is useful for manufacturing a medicament for the treatment of acromegaly, gigantism, growth hormone (GH) deficiency, Turner's syndrome, renal failure, osteoporosis, diabetes mellitus, cancer, obesity, insulin resistance, hyperlipidaemia, hypertension, anaemia, autoimmune and infectious diseases, and inflammatory disorders including rheumatoid arthritis (interleukin (IL)-6 chimaera).

CC The present sequence represents the fusion protein agent of the invention being the GHlinkGHR construct (growth hormone/growth hormone receptor linked by a synthetic peptide linker).

DR	WPI; 1989-300419/41.	SQ	Sequence	638 AA;
DR	N-PSDB; AAN91325.	Query Match	88 4%	Score 38;
XX	Modulating growth hormone receptor activity - by immunising animal against growth hormone receptor extracellular domain deriv. to raise antisera.	Best Local Similarity	100.0%	DB 9; Length 638;
PT		Matches	6;	Pred. No. 38;
PT		Conservative	0;	Mismatches 0;
PT		Indels	0;	Gaps 0;
XX		Qy	1 CEEDEFY 6	
PS	Disclosure; Fig. 2a-c; 18pp; English.	Db	259 CEEDEFY 264	
XX		RESULT 14		
CC	An animal can be immunised against its growth hormone receptor by vaccinating against a growth hormone receptor extracellular domain deriv.	ID	AAM33394 standard; Protein; 638 AA.	
CC	predetermined to raise polyclonal antisera which affect the receptor as a growth hormone agonist. This method enables continuous growth of target tissues without frequent hormone admin.	XX	AAM33394;	
CC		AC	AC	
XX	Sequence 637 AA;	XX	XX	
Query Match	88 4%	Key	Key	Location/Qualifiers
Best Local Similarity	100.0%	Peptide	1..18	
Matches	6;	FT	label= Sig_peptide	
Conservative	0;	FT	247..259	
Mismatches	0;	FT	/note= "transmembrane domain"	
Indels	0;	FT	375	
Gaps	0;	FT	/note= "translated codon is Ser in clone ghr.210 and ghr.501"	
DE		FT		
XX		XX		
XX		XX		
KW	Growth hormone receptor; gigantism; acromegaly.	XX		
XX		PN	US5688763-A.	
KW		XX		
XX		PD	18-NOV-1997.	
OS		XX		
XX		PF	12-JUN-1987;	
AC		XX		
XX		PR	08-JAN-1993;	
AAP81326		XX		
XX		PR	12-JUN-1987;	
XX		PR	28-JUN-1991;	
XX		PR	25-MAY-1994;	
XX		XX		
XX		PA	(CODO/ COLOST P C.	
XX		PA	(HANN/ HAMMONDS R G.	
XX		PA	(LBUN/ LEUNG D W.	
XX		PA	(SPEN/ SPENCER S A.	
XX		PA	(WOOD/ WOOD W I.	
PN	W08809818-A.	XX		
XX		PI	Colosi PC, Hammonds RG,	
XX		XX	Leung DW,	
XX		DR	Spencer SA, Wood WI;	
XX		WPI; 1998-008010/01.		
XX		DR	N-PSDB; AAT94063.	
XX		XX		
XX	15-DEC-1988.	PT	Human and rabbit growth hormone receptor protein - useful to treat disorders associated with overexpression, e.g. gigantism and acromegaly.	
XX		PT		
XX	10-JUN-1988;	PT		
XX	88WO-US02008.	PT		
XX		PT		
XX	12-JUN-1987;	PT		
XX	87US-0062542.	PT		
XX		XX		
PA	(GETH) GENENTECH INC.	PI		
XX		XX		
XX	Hammonds RG, Leung DW, Spencer SA, Wood WI;	DR		
XX		WPI; 1998-368632/51.		
XX		DR		
XX		DR	N-PSDB; AAN81716.	
XX		XX		
XX	New pure growth hormone receptor and binding protein - for treating growth hormone abnormalities, and new encoding DNA sequences.	PS	Claim 2; Fig 8a; 60pp; English.	
XX		XX		
PS	Disclosure; 1 pp; English.	PS		
XX		XX		
CC	The sequence was deduced from a clone isolated from an adult liver CC DNA lambda gt10 library. The DNA can be inserted into an CC expression vector for prod. of the recombinant GHR which is used CC to treat GH related disorders such as gigantism and acromegaly. CC A hydroxymethyl plot revealed an extracellular GH binding domain, a CC transmembrane domain, and an intracellular signalling domain. Eight CC potential N-linked glycosylation sites are predicted. See also AAP81327 and AAN81718-9.	CC	This protein sequence comprises human growth hormone receptor. The CC amino acid sequence was deduced from cDNA clones (see AAT4063) CC obtained from a human liver cDNA library, and shows 84 % identity CC to the rabbit growth hormone receptor (see AAW3395). Human CC growth hormone receptor, its derivatives in which the cytoplasmic CC or transmembrane domains are deleted, and growth hormone binding CC proteins comprising amino acids 190-246 or 1-324 of the mature CC protein, can be used to treat disorders associated with growth CC hormone over-expression, e.g. gigantism and acromegaly. The CC binding protein may also be used to increase the stability and CC	

CC efficacy of growth hormone in vivo.
 XX
 SQ Sequence 638 AA;
 Query Match 88.4%; Score 38; DB 19; Length 638;
 Best Local Similarity 100.0%; Pred. No. 38;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 CEEDFY 6
 Db 259 CEEDFY 264

RESULT 15
 ABB11437 standard; peptide: 648 AA.
 ID ABB11437
 XX
 AC ABB11437;
 XX
 DT 11-JAN-2002 (first entry)
 XX
 DE Human growth hormone receptor homologue, SEQ ID NO:1807.
 KW Human; cytokine; cell proliferation; cell differentiation; growth factor;
 haemopoiesis regulation; tissue growth; immunomodulator; activin;
 KW inhibitor; chemotaxis; chemokines; thrombolytic; oncogenesis;
 KW proliferation; metastasis; cancer; tumour; haemopoietic disorder;
 KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
 KW chronic inflammatory condition; proliferative retinopathy;
 KW atherosclerosis; coronary heart disease; arterial ischaemia;
 KW bone disorder; osteoporosis; vascular growth disorder;
 KW tissue regeneration; wound healing; infection; immune disorder;
 KW cell culture; drug screening; gene therapy; antiinflammatory;
 KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;
 KW cytostatic; osteopathic; vasotropic; cardiant; viricide; antibacterial;
 KW antifungal; vulnerary; antilulcer.
 XX
 OS Homo sapiens.
 XX
 PN WO200157188-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 05-FEB-2001; 2001WO-US03800.
 XX
 PR 03-FEB-2000; 2000US-0496914.
 PR 27-APR-2000; 2000US-0560875.
 XX
 PA (HYSEQ) HYSEQ INC.
 XX
 Tang YT, Liu C, Drmanac RT;
 WPI; 2001-457740/49.
 DR N-PSDB ABA08681.

XX Human Proteins and DNA encoding sequences useful for preventing, treating or ameliorating a medical condition in a mammalian subject -
 PR e.g. arthritis and cancer -
 XX
 PS Claim 20: Page 189-190; 1963pp; English.
 XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and sequences ABA08225-ABA09574 represent nucleic acids encoding them. The invention also relates to vectors and recombinant host cells comprising a nucleotide of the invention, methods of producing the novel polypeptides, antibodies against the polypeptides, methods of detecting the nucleotides or polypeptides in a sample, and methods of identifying compounds which bind to polypeptides of the invention. Although novel, many of the polypeptides of the invention have homology to known proteins, thereby giving an insight into their probable biological activities, and hence potential therapeutic applications. The polypeptides of the invention may have various activities, including cytokine, cell proliferation or cell differentiation activities; stem cell growth factor activity;

CC haemopoiesis regulatory activity; tissue growth activity;
 CC immunomodulatory activity; activin- or inhibin-related activities;
 CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
 CC thrombolytic activities; receptor or ligand activities; or may be
 CC involved in oncogenesis, cancer cell proliferation or metastasis.
 CC Depending on their biological activities, polypeptides and nucleotides of
 CC the invention are useful for preventing, treating or ameliorating medical
 CC conditions, e.g., by protein or gene therapy. Such conditions include
 CC cancers, haemopoietic disorders (e.g., myeloid or lymphoid cell
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
 CC proliferative retinopathy, atherosclerosis, coronary heart disease,
 CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
 CC vascular growth. Polypeptides involved with tissue regeneration and
 CC repair (or nucleic acids encoding them) may be used to promote wound
 CC healing (e.g., of burns, incisions and ulcers), while those with
 CC immunomodulatory activities may be used in the treatment of viral,
 CC bacterial and fungal infections in addition to immune disorders.
 CC Polypeptides with growth factor activity may be used in cell cultures to
 CC promote cell growth. For example, such polypeptides may be used to
 CC manipulate stem cells in culture to give rise to neuroepithelial cells
 CC that can be used to augment or replace cells damaged by illness,
 CC autoimmune disease or accidental damage. The polypeptides and nucleotides
 CC may also be used in the diagnosis of the above conditions, and in drug
 CC screening techniques. The present sequence represents a novel human
 CC polypeptide of the invention.
 XX
 SQ Sequence 648 AA;
 Query Match 88.4%; Score 38; DB 22; Length 648;
 Best Local Similarity 100.0%; Pred. No. 38;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 CEEDFY 6
 Db 259 CEEDFY 274

Search completed: February 12, 2003, 11:44:39
 Job time : 30 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2003, 11:43:40 ; Search time 10.7333 Seconds
(without alignments)
19.189 Million cell updates/sec

Title: US-09-660-302c-7
Perfect score: 43
Sequence: 1 CEEDEFYR 7

Scoring table: BLOSUM62

Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA : *
1: /cgn2_6/ptodata/1/1aa/5A_COMB_pep: *
2: /cgn2_6/ptodata/1/1aa/5B_COMB_pep: *
3: /cgn2_6/ptodata/1/1aa/6A_COMB_pep: *
4: /cgn2_6/ptodata/1/1aa/6B_COMB_pep: *
5: /cgn2_6/ptodata/1/1aa/pcnus_cmb_pep: *
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	38	88.4	620	4	US-09-000-145-1		Sequence 1, Appli
2	36	83.7	84	2	US-08-465-380-59		Sequence 59, Appli
3	36	83.7	84	2	US-08-486-397-59		Sequence 59, Appli
4	36	83.7	84	2	US-08-486-399-59		Sequence 59, Appli
5	36	83.7	84	2	US-08-461-965-59		Sequence 59, Appli
6	36	83.7	84	2	US-08-534-661-59		Sequence 59, Appli
7	36	83.7	84	3	US-09-249-472-59		Sequence 59, Appli
8	36	83.7	84	3	US-09-249-472-59		Sequence 59, Appli
9	36	83.7	84	3	US-09-249-471-59		Sequence 59, Appli
10	36	83.7	84	3	US-08-809-455-59		Sequence 59, Appli
11	36	83.7	84	3	US-09-249-461-59		Sequence 59, Appli
12	36	83.7	84	3	US-09-249-448-59		Sequence 59, Appli
13	36	83.7	91	2	US-08-465-380-128		Sequence 128, Appli
14	36	83.7	91	2	US-08-480-478-50		Sequence 50, Appli
15	36	83.7	91	2	US-08-486-397-128		Sequence 128, Appli
16	36	83.7	91	2	US-08-486-399-128		Sequence 128, Appli
17	36	83.7	91	2	US-08-461-965-128		Sequence 128, Appli
18	36	83.7	91	2	US-08-526-110A-50		Sequence 50, Appli
19	36	83.7	91	2	US-08-634-641-128		Sequence 128, Appli
20	36	83.7	91	3	US-09-249-471-128		Sequence 128, Appli
21	36	83.7	91	3	US-09-249-472-128		Sequence 128, Appli
22	36	83.7	91	3	US-09-249-451-128		Sequence 128, Appli
23	36	83.7	91	3	US-09-249-448-128		Sequence 128, Appli
24	36	83.7	91	3	US-09-249-441-128		Sequence 128, Appli
25	36	83.7	91	3	US-09-249-448-128		Sequence 128, Appli
26	34	79.1	723	6	5200183-4		Patent No. 5200183
27	33	76.7	75	2	US-08-465-380-6		Sequence 6, Appli

ALIGNMENTS

RESULT 1	US-09-000-145-1						
	; Sequence 1, Application US/09000145						
	; Patent No. 6169172						
	; GENERAL INFORMATION:						
	; APPLICANT: DEVAUCHELLE, Gerard						
	; APPLICANT: GARNIER, Laurence						
	; APPLICANT: CAHOREAU, Claire						
	; APPLICANT: CERUTTI, Martine						
	; TITLE OF INVENTION: USE OF A PROLACTIN RECEPTOR OR GROWTH HORMONE RECEPTOR						
	; FILE REFERENCE: 0384-0047-0XPCT						
	; CURRENT APPLICATION NUMBER: US/09/000,145						
	; CURRENT FILING DATE: 1998-03-16						
	; EARLIER APPLICATION NUMBER: PCT/FR96/01237						
	; EARLIER FILING DATE: 1996-08-02						
	; EARLIER APPLICATION NUMBER: FR 95/09420						
	; NUMBER OF SEQ ID NOS: 6						
	; SOFTWARE: PatentIn Ver. 2.0						
	; SEQ ID NO: 1						
	; LENGTH: 620						
	; TYPE: PRT						
	; ORGANISM: Homo sapiens						
	; US-09-000-145-1						
	Query Match	88.4%	Score 38;	DB 4;	Length 620;		
	Best Local Similarity	100.0%	Pred. No. 15;				
	Matches 6;	Conservative, 0;	Mismatches 0;	Indels 0;	Gaps 0;		
Qy	1 CEEDEFY 6						
Db	111111						
	RESULT 2						
	US-08-465-380-59						
	; Sequence 59, Application US/08465380						
	; Patent No. 5863894						
	; GENERAL INFORMATION:						
	; APPLICANT: George P. Vlasiuk, Patric H. Stanssens,						
	; APPLICANT: Joris H.I. Mensens, Marc J. Lauwers,						
	; APPLICANT: Yves R. Laroche, Laurent S. Jespers,						
	; APPLICANT: Yannick G.J. Ganssemans, Matthew Moyle,						
	; APPLICANT: Peter W. Bergum						
	; TITLE OF INVENTION: NEMATODE-EXTRACTED ANTICOAGULANT						
	; TITLE OF INVENTION: PROTEIN						
	; NUMBER OF SEQUENCES: 356						
	; CORRESPONDENCE ADDRESS:						
	; ADDRESSEE: Lyon & Lyon						

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,397
; FILING DATE: June 5, 1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/326,110
; FILING DATE: October 18, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: BIGGS, SUZANNE L.
; REGISTRATION NUMBER: 30,158
; REFERENCE/DOCKET NUMBER: 213/769
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 84 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: Anyclostoma caninum
; US-08-486-397-59

Query Match Score 83.7%; Score 36; DB 2; Length 84;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 0; Mismatches 1; Indels 0;
Gaps 0;

; RESULT 4
; US-08-486-399-59
; Sequence 59, Application US/08486399
; Patent No. 5866543
; GENERAL INFORMATION:
; APPLICANT: George P. Vlasuk, Patric H. Stanssens,
; Joris H.L. Mensens, Marc J. Lauwers, Yves R. Laroch, Laurent S. Jespers, Yannick G.J. Gansmans, Matthew Moyle, Peter W. Bergum
; TITLE OF INVENTION: NEMATODE-EXTRACTED ANTICOAGULANT
; TITLE OF INVENTION: PROTEIN
; NUMBER OF SEQUENCES: 356
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,399
; FILING DATE: June 5, 1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/326,110
; FILING DATE: October 18, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: BIGGS, SUZANNE L.
; REGISTRATION NUMBER: 30,158
; REFERENCE/DOCKET NUMBER: 213/770
; TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE: Ancylostoma caninum
 US-08-486-399-59

Query Match 83.7%; Score 36; DB 2; Length 84;
 Best Local Similarity 85.7%; Pred. No. 5; Mismatches 0; Gaps 0;
 Matches 6; Conservative 0; Indels 0; Gaps 0;

Y 1 CEEDEFYR 7
 ||| |||
 Db 52 CEEGFYR 58

RESULT 5
 US-08-461-965-59
 Sequence 59, Application US/08461965
 Patent No. 5872098
 GENERAL INFORMATION:
 APPLICANT: George P. Vlasuk, Patric H. Stanssens,
 ADDRESS: Joris H.L. Mensens, Marc J. Lauwersys,
 CITY: Yves R. Laroche, Laurent S. Jespers,
 APPLICANT: Yannick G.J. Gansmans, Matthew Moyle,
 APPLICANT: Peter W. Bergum
 TITLE OF INVENTION: NEMATODE-EXTRACTED ANTICOAGULANT
 NUMBER OF SEQUENCES: 356
 CORRESPONDENCE ADDRESS:
 STREET: 633 West Fifth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/634,641
 FILING DATE: April 19, 1996
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/13231
 FILING DATE: October 17, 1995
 APPLICATION NUMBER: 08/486,399
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/486,397
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/465,380
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/461,965
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/326,110
 FILING DATE: October 18, 1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUSANNE L.
 REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 210/243
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE: Ancylostoma caninum
 US-08-461-965-59

Query Match 83.7%; Score 36; DB 2; Length 84;
 Best Local Similarity 85.7%; Pred. No. 5; Mismatches 1; Indels 0; Gaps 0;
 Matches 6; Conservative 0; Indels 1; Gaps 0;

RESULT 6
 US-08-634-641-59
 Sequence 59, Application US/08634641
 Patent No. 595294
 GENERAL INFORMATION:
 APPLICANT: Vlasuk, George P. Vlasuk
 ADDRESS: Stanssens, Patrick Eric Hugo
 CITY: Mensens, Joris Hilda Lieven
 APPLICANT: Lauwersys, Marc Josef
 ADDRESS: Laroche, Yves Rene
 CITY: Jespers, Laurent Stephane
 APPLICANT: Gansmans, Yannick Georges Jozef
 ADDRESS: Moyle, Matthew
 CITY: Bergum, Peter W.
 TITLE OF INVENTION:
 APPLICANT: PROTEIN
 NUMBER OF SEQUENCES: 356
 CORRESPONDENCE ADDRESS:
 ADDRESS: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/634,641
 FILING DATE: April 19, 1996
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/13231
 FILING DATE: October 17, 1995
 APPLICATION NUMBER: 08/486,399
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/486,397
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/465,380
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/461,965
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/326,110
 FILING DATE: October 18, 1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUSANNE L.
 REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 210/243
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE: Ancylostoma caninum
 ORGANISM: Ancylostoma caninum

S-08-634 641-59

Query Match 83.7%; Score 36; DB 2; Length 84;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Y 1 CEEDEFYR 7
b 52 CEEGFYR 58

RESULT 7
S-09-249-471-59
Sequence 59 Application US/09249471
Patent No. 6040411

GENERAL INFORMATION:
APPLICANT: Vlasek, George Phillip
APPLICANT: Stanssens, Patrick Eric Hugo
APPLICANT: Messens, Joris Hilda Lieven
APPLICANT: Lauwersys, Marc Josef
APPLICANT: Laroche, Yves Rene
APPLICANT: Jespers, Laurent Stephane
APPLICANT: Ganssemans, Yannick Georges Jozef
APPLICANT: Moyle, Matthew
APPLICANT: Bergum, Peter W.

TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE
TITLE OF INVENTION: INHIBITORS AND ANTICOAGULANT
TITLE OF INVENTION: PROTEIN
NUMBER OF SEQUENCES: 356

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/249,471
FILING DATE:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/809,455
FILING DATE: April 17, 1997
APPLICATION NUMBER: PCT/US95/13231
FILING DATE: October 17, 1995
APPLICATION NUMBER: 08/486,399
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/486,397
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/485,380
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/461,965
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/326,110
FILING DATE: October 18, 1994

ATTORNEY/AGENT INFORMATION:
NAME: BIGGS, SUZANNE L.
REGISTRATION NUMBER: 30,158
REFERENCE/DOCKET NUMBER: 216/270

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 84 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: peptide
ORIGINAL SOURCE:
ORGANISM: Ancylostoma caninum
US-09-249-471-59

Query Match 83.7%; Score 36; DB 3; Length 84;
Best Local Similarity 85.7%; Pred. No. 5;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CEEDEFYR 7
Db 52 CEEGFYR 58

RESULT 8
US-09-249-472-59
Sequence 59 Application US/09249472
Patent No. 6046318

GENERAL INFORMATION:
APPLICANT: Vlasek, George Phillip
APPLICANT: Stanssens, Patrick Eric Hugo
APPLICANT: Messens, Joris Hilda Lieven
APPLICANT: Lauwersys, Marc Josef
APPLICANT: Laroche, Yves Rene
APPLICANT: Jespers, Laurent Stephane
APPLICANT: Ganssemans, Yannick Georges Jozef
APPLICANT: Moyle, Matthew
APPLICANT: Bergum, Peter W.

TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE
TITLE OF INVENTION: INHIBITORS AND ANTICOAGULANT
TITLE OF INVENTION: PROTEIN
NUMBER OF SEQUENCES: 356

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/249,472
FILING DATE:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/809,455
FILING DATE: April 17, 1997
APPLICATION NUMBER: PCT/US95/13231
FILING DATE: October 17, 1995
APPLICATION NUMBER: 08/486,399
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/486,397
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/485,380
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/461,965
FILING DATE: June 5, 1995
APPLICATION NUMBER: 08/326,110
FILING DATE: October 18, 1994

ATTORNEY/AGENT INFORMATION:
NAME: BIGGS, SUZANNE L.
REGISTRATION NUMBER: 30,158
REFERENCE/DOCKET NUMBER: 216/270

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 84 amino acids
TYPE: amino acid

INFORMATION FOR SEQ ID NO: 59:

SEQUENCE CHARACTERISTICS:

LENGTH: 84 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: Peptide

ORIGINAL SOURCE:

ORGANISM: Ancylostoma caninum

US-09-249-451-59

Query Match 83.7%; Score 36; DB 3; Length 84;

Best Local Similarity 85.7%; Pred. No. 5;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 52 CEEGFYR 58

RESULT 9

Sequence 59, Application US/09249451

PATENT NO. 6087487

GENERAL INFORMATION:

APPLICANT: Vlasuk, George Phillip

APPLICANT: Stanssens, Patrick Eric Hugo

APPLICANT: Messens, Joris Hilda Lieven

APPLICANT: Lauwereys, Marc Josef

APPLICANT: Larocque, Yves Rene

APPLICANT: Jaspers, Laurent Stephane

APPLICANT: Gansmans, Yannick Georges Jozef

APPLICANT: Moyle, Matthew

APPLICANT: Bergum, Peter W.

TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE

TITLE OF INVENTION: INHIBITORS AND ANTICOGULANT

TITLE OF INVENTION: PROTEIN

NUMBER OF SEQUENCES: 356

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C., DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/249,451

FILING DATE: April 17, 1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/13231

FILING DATE: October 17, 1995

APPLICATION NUMBER: 08/486,399

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/486,397

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/465,380

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/461,965

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/326,110

FILING DATE: October 18, 1994

ATTORNEY/AGENT INFORMATION:

NAME: BIGGS, SUZANNE L.

REGISTRATION NUMBER: 30-158

REFERENCE/DOCKET NUMBER: 216/270

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

SEQUENCE CHARACTERISTICS:

LENGTH: 84 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: Peptide

ORIGINAL SOURCE:

ORGANISM: Ancylostoma caninum

US-09-249-451-59

Query Match 83.7%; Score 36; DB 3; Length 84;

Best Local Similarity 85.7%; Pred. No. 5;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 52 CEEGFYR 58

RESULT 10

US-08-809-455-59

Sequence 59, Application US/08809455

PATENT NO. 6090916

GENERAL INFORMATION:

APPLICANT: Viasuk, George Phillip

APPLICANT: Stanssens, Patrick Eric Hugo

APPLICANT: Messens, Joris Hilda Lieven

APPLICANT: Lauwereys, Marc Josef

APPLICANT: Larocque, Yves Rene

APPLICANT: Jaspers, Laurent Stephane

APPLICANT: Gansmans, Yannick Georges Jozef

APPLICANT: Moyle, Matthew

APPLICANT: Bergum, Peter W.

TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE

TITLE OF INVENTION: INHIBITORS AND ANTICOGULANT

NUMBER OF SEQUENCES: 356

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C., DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/809,455

FILING DATE: April 17, 1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/13231

FILING DATE: October 17, 1995

APPLICATION NUMBER: 08/486,399

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/486,397

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/486,397

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/465,397

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/465,380

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/461,965

FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/326,110

FILING DATE: October 18, 1994

ATTORNEY/AGENT INFORMATION:

NAME: BIGGS, SUZANNE L.

REGISTRATION NUMBER: 30-158

REFERENCE/DOCKET NUMBER: 216/270

NAME: BIGGS, SUZANNE L.

REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 216/270
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEX: (213) 955-0440
 TELLEX: 67-3510
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE:
 ORGANISM: Anyclostoma caninum
 US-08-809-455-59

Query Match 83.7%; Score 36; DB 3; Length 84;
 Best Local Similarity 85.7%; Pred. No. 5;
 Matches 6; Conservative 0; Mismatches 0;
 Gaps 0;
 Indels 0;

Qy 1 CEEDFYR 7
 ||||| 52 CEEGFYR 58

RESULT 11
 US-09-249-461-59
 Sequence 59, Application US/09249461
 Patent No. 6096877

GENERAL INFORMATION:
 APPLICANT: Vlasuk, George Phillip
 APPLICANT: Stanssens, Patrick Eric Hugo
 APPLICANT: Messens, Joris Hilda Lieven
 APPLICANT: Lauwers, Marc Josef
 APPLICANT: Laroche, Yves Rene
 APPLICANT: Jespers, Laurent Stephane
 APPLICANT: Ganssemans, Yannick Georges Jozef
 APPLICANT: Moyle, Matthew
 APPLICANT: Bergum, Peter W.
 TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE
 TITLE OF INVENTION: INHIBITORS AND ANTICOAGULANT
 TITLE OF INVENTION: PROTEIN
 NUMBER OF SEQUENCES: 356
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 MB
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/249,461
 FILING DATE: April 17, 1997
 APPLICATION NUMBER: 08/809,455
 FILING DATE: October 17, 1995
 APPLICATION NUMBER: 08/486,399
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/486,397
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/465,380
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/461,965
 FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/326,110
 FILING DATE: October 18, 1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUZANNE L.
 REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 216/270
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEX: (213) 955-0440
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE:
 ORGANISM: Anyclostoma caninum
 US-09-249-461-59

Query Match 83.7%; Score 36; DB 3; Length 84;
 Best Local Similarity 85.7%; Pred. No. 5;
 Matches 6; Conservative 0; Mismatches 1;
 Gaps 0;
 Indels 0;

Qy 1 CEEDFYR 7
 ||||| 52 CEEGFYR 58

RESULT 12
 US-09-249-448-59
 Sequence 59, Application US/09249448
 Patent No. 6121435

GENERAL INFORMATION:
 APPLICANT: Vlasuk, George Phillip
 APPLICANT: Stanssens, Patrick Eric Hugo
 APPLICANT: Messens, Joris Hilda Lieven
 APPLICANT: Lauwers, Marc Josef
 APPLICANT: Laroche, Yves Rene
 APPLICANT: Jespers, Laurent Stephane
 APPLICANT: Ganssemans, Yannick Georges Jozef
 APPLICANT: Moyle, Matthew
 APPLICANT: Bergum, Peter W.
 TITLE OF INVENTION: NEMATODE-EXTRACTED SERINE PROTEASE
 NUMBER OF SEQUENCES: 356
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 MB
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/249,448
 FILING DATE: April 17, 1997
 APPLICATION NUMBER: 08/809,455
 FILING DATE: April 17, 1997
 APPLICATION NUMBER: PCT/US95/13231
 FILING DATE: October 17, 1995
 APPLICATION NUMBER: 08/465,399
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/486,397
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/461,965
 FILING DATE: June 5, 1995

APPLICATION NUMBER: 08/465,380
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/461,965
 FILING DATE: June 5, 1995
 APPLICATION NUMBER: 08/326,110
 FILING DATE: October 18, 1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUZANNE L.
 REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 216/270
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 59:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 84 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ORIGINAL SOURCE:
 ORGANISM: Ancylostoma caninum
 US-09-249-448-59

Query Match Score 36; DB 3; Length 84;
 Best Local Similarity 85.7%; Pred. No. 5;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CEEDFYR 7
 Db 52 CEEGFYR 58

RESULT 13
 US-08-465-380-128
 Sequence 128, Application US/08465380
 Patent No. 5863894
 GENERAL INFORMATION:
 APPLICANT: George P. Vlasuk, Patric H. Stanssens,
 APPLICANT: Joris H.L. Mensens, Marc J. Lauwersys,
 APPLICANT: Yves R. Laroche, Laurent S. Jespers,
 APPLICANT: Yannick G.J. Gansens, Matthew Moyle,
 APPLICANT: Peter W. Bergum
 TITLE OF INVENTION: NEMATODE-EXTRACTED ANTICOAGULANT
 TITLE OF INVENTION: PROTEIN
 NUMBER OF SEQUENCES: 356
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/465,380
 FILING DATE: June 5, 1995
 CLASSIFICATION: 530
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/326,110
 FILING NUMBER: 08/326,110
 FILING DATE: October 18, 1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUZANNE L.
 REGISTRATION NUMBER: 30,158
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600

Query Match Score 36; DB 2; Length 91;
 Sequence 50, Application US/08480478
 Patent No. 5864009
 GENERAL INFORMATION:
 APPLICANT: PATRICK ERIC
 APPLICANT: HUGO STANSSENS; JORIS HILDA
 APPLICANT: LIEVEN MESENS; MARC JOZEF
 APPLICANT: LAUWREYS; YVES RENE LAROCHE;
 APPLICANT: LAURENT STEPHANE JESPERS; and
 APPLICANT: YANNICK GEORGES JOZEF
 APPLICANT: GANSEMANNS
 TITLE OF INVENTION: NEMATODE-EXTRACTED ANTI-
 COAGULANT PROTEIN
 NUMBER OF SEQUENCES: 86
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: Suite 4700
 STREET: 633 West Fifth Street
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: FASSEQ Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/480,478
 FILING DATE: 06-JUN-1995
 PRIORITY DATA:
 PRIORITY NUMBER: 530
 PRIORITY DATE: 18-OCTOBER-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: BIGGS, SUZANNE L.
 REGISTRATION NUMBER: 30,158
 REFERENCE/DOCKET NUMBER: 208/290
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 50:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 91 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 US-08-480-478-50

Query Match Score 36; DB 2; Length 91;

Best Local Similarity 85.7%; Pred. No. 5.4;
Matches 6; Conservative 0; Mismatches

Qy 1 CEEDEFYR 7
Db 59 CEEGFYR 65

RESULT 15 US-08-486-397-128

; Sequence 128, Application US/08486397
; Patent No. 5066542

; GENERAL INFORMATION:

; APPLICANT: George P. Vlasuk, Patrick H. Stanssens,
; Joris H.L. Mensens, Marc J. Lauverys,
; Yves R. Laroche, Laurent S. Jaspers,
; Yannick G.J. Gansmans,
; Peter W. Bergum, Matthew Moyle,
; Peter W. Bergum
; TITLE OF INVENTION: NEMATODE-EXTRACTED ANTICOAGULANT
; NUMBER OF SEQUENCES: 357

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; SUITE: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C., DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/486,397

; FILING DATE: June 5, 1995

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/326,110

; FILING DATE: October 18, 1994

; ATTORNEY/AGENT INFORMATION:

; NAME: BIGGS, SUZANNE L.

; REGISTRATION NUMBER: 30,158

; REFERENCE/DOCKET NUMBER: 213/269

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEX: 67-3510

; INFORMATION OR SEQ ID NO: 128:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 91 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; ORIGINAL SOURCE: peptide

; ORGANISM: Ancyclostoma caninum

; US-08-486-397-128

Query Match 83.7%; Score 36; DB 2; Length 91;
Best Local Similarity 85.7%; Pred. No. 5.4;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CEEDEFYR 7
Db 59 CEEGFYR 65

GenCore version 5.1.3
 Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2003, 11:39:59 ; Search time 6.53333 Seconds
 44.439 Million cell updates/sec

Title: US-09-660-302C-7
 Perfect score: 43
 Sequence: 1 CEEDEYR 7

Scoring table: BLOSUM62

Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : SwissProt_40;*

Pre. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	38	88.4	638	1	GHR_HUMAN	P10912	homo sapien
2	38	88.4	638	1	GHR_MACMU	P79194	macaca mulatta
3	36	83.7	20	1	UN05_PTPNS	P81674	pinus pinas
4	36	83.7	364	1	MYCL_HUMAN	P12524	homo sapien
5	36	83.7	368	1	MYCL_MOUSE	P10166	mus musculus
6	36	83.7	388	1	LHX9_HUMAN	Q8nq69	homo sapien
7	36	83.7	388	1	LHX9_MOUSE	Q9wuh2	mus musculus
8	36	83.7	406	1	LHX2_HUMAN	P50458	homo sapien
9	36	83.7	406	1	LHX2_MOUSE	P9z0s2	mus musculus
10	36	83.7	426	1	LHX2_RAT	P36198	rat
11	35	81.4	372	1	COLB_ARATH	Q8ses5	arabidopsis
12	34	79.1	599	1	BAL_MOUSE	P04285	mus musculus
13	34	79.1	612	1	BAL_RAT	P01892	rat
14	34	79.1	707	1	NRDD_HAEIN	P43752	haemophilus
15	33	76.7	86	1	Y576_ARCFU	P29679	archaeoglob
16	32	74.4	154	1	PYRL_BUCAI	P57451	bucinaea ap
17	32	74.4	367	1	LHX4_HUMAN	Q96992	homo sapien
18	32	74.4	367	1	LHX4_MOUSE	P53776	mus musculus
19	32	74.4	395	1	LHX3_CHICK	P53412	gallus gallus
20	32	74.4	415	1	THDI_BACH	Q9kc63	bacillus ha
21	32	74.4	486	1	HH1R_RAT	P31390	rat
22	32	74.4	487	1	HH1R_HUMAN	P35336	homo sapien
23	32	74.4	488	1	HH1R_CAVPO	P31389	cavia porcellus
24	32	74.4	488	1	HH1R_MOUSE	P70174	mus musculus
25	32	74.4	491	1	HH1R_BOVIN	P30556	bos taurus
26	32	74.4	581	1	NET2_CHICK	P290923	gallus gallus
27	32	74.4	606	1	NET1_CHICK	P019022	gallus gallus
28	32	74.4	647	1	PEPO_LACHE	Q32071	lactobacillus
29	32	74.4	647	1	SK01_YEAST	Q02100	saccharomyces
30	32	74.4	727	1	NEPA_DRONE	Q24567	drospophilia
31	32	74.4	796	1	COPP_SCARPO	P29331	schizosaccharomyces
32	32	74.4	976	1	EPAA_HUMAN	P34757	homo sapien
33	32	74.4	1005	1	EPAS5_RAT	RN	

ALIGNMENTS

Score:	Query	Match	Length	DB	ID	Description	
34	32	74.4	1037	1	EPAS5_HUMAN	P54756	homo sapien
35	32	74.4	1696	1	PCK5_BRACI	Qnj15	branchiosco
36	31	72.1	90	1	YHCO_ECOLI	P46480	escherichia
37	31	72.1	148	1	FER2_ARATH	P04090	arabidopsis
38	31	72.1	230	1	YGEA_ECOLI	P03813	escherichia
39	31	72.1	334	1	P32277	bacterioph	
40	31	72.1	385	1	YHHT7_SACDO	P41907	saccharomy
41	31	72.1	401	1	T11B_HUMAN	P00300	homo sapien
42	31	72.1	401	1	T11B_MOUSE	Q08712	mus musculus
43	31	72.1	401	1	T11B_RAT	Q08727	rattus norvegicus
44	31	72.1	597	1	BAL_BOVIN	P30122	bos taurus
45	31	72.1	621	1	GIDA_HELPY	P36138	helicobacte

RESULT 1						
GHR_HUMAN	STANDARD;	PRT;	638 AA.			
ID GHR_HUMAN						
AC P10912;						
DT 01-JUL-1989 (Rel. 11, Created)						
DT 01-JUL-1989 (Rel. 11, Last sequence update)						
DT 16-OCT-2001 (Rel. 40, Last annotation update)						
DE Growth hormone receptor precursor (GH receptor) (Serum binding protein).						
GN GHR.						
OS Homo sapiens (Human).						
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;						
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.						
OX NCBI_TaxID=9606;						
RN [1]						
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.						
RC TISSUE-Liver						
RX MEDLINE-88065896; PubMed=2825030;						
RA Leung D.W., Spencer S.A., Cachianes G., Hammonds R.G., Collins C.,						
RA Keret R., Rotwein P.S., Parks J.S., Laron Z., Wood W.I.;						
RA Henzel W.J., Barnard R., Waters M.J., Wood W.I.;						
RT "Growth hormone receptor and serum binding protein: purification, cloning and expression.";						
RT Nature 330:537-543(1988).						
RL RN						
RP SEQUENCE FROM N.A.						
RX MEDLINE-90046742; PubMed=2813379;						
RA Godowski P.J., Leung D.W., Meacham L.R., Galgani J.P., Hellmiss R.,						
RA Keret R., Rotwein P.S., Parks J.S., Laron Z., Wood W.I.;						
RT "Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism.";						
RT Proc. Natl. Acad. Sci. U.S.A. 86:8083-8087(1989).						
RL RN						
RP DISULFIDE BONDS.						
RX MEDLINE=90123957; PubMed=2406245;						
RA Fuhr G., Muller K., Bass S.M., McFarland N., Brochier M.,						
RA Bourrel J.H., Light D.R., Wells J.A.,						
RA Amselem S., Duquesnoy P., Attree O., Novelli G., Bousmina S.,						
RA Postelvintay M.-C., Goossens M.;						
RT "Laron dwarfism and mutations of the extracellular binding domain.";						
RT J. Biol. Chem. 265:3111-3115(1990).						
RL RN						
RP VARIANT LARON DWARFISM SER-114.						
RX MEDLINE=89334829; PubMed=2779634;						
RA Amselem S., Duquesnoy P., Attree O., Novelli G., Bousmina S.,						
RA Valleix S., Goossens M.;						
RT "Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome.";						
RT Hum. Mol. Genet. 2:355-359(1993).						
RN [6]						

VARIANT LARON DWARFISM HIS-170.
 MEDLINE=94185615; PubMed=817822;
 RX Dusquesnoy P., Sobrier M.-L., Duriez B., Dastot F., Buchanan C.R.,
 RA Savage M.O., Preece M.A., Craescu C.T., Blouquit Y., Goossens M.,
 RA Amselem S.;
 RT "A single amino acid substitution in the exoplasmic domain of the
 human growth hormone (GH) receptor confers familial GH resistance
 (Laron syndrome) with positive GH-binding activity by abolishing
 receptor homodimerization.";
 RT receptor homodimerization.
 RL EMBO J. 13:13886-1395(1994).
 RN [7]
 RP VARIANT IDIOPATHIC SHORT STATURE LYS-62; CYS-179 AND ASP-242.
 RX MEDLINE=96013502; PubMed=7565946;
 RA Goddard A.D., Covello R., Luh S. M., Clackson T., Attie K. M.,
 RA Goddard A.D., Rundle A.C., Wells J.A., Carlsson L.M.S.;
 RT "Mutations of the growth hormone receptor in children with idiopathic
 short stature.";
 RL New Engl. J. Med. 333:1093-1098(1995).
 RN [8]
 RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 19-256.
 RX MEDLINE=93196577; PubMed=1549797;
 RA de Vos A.M., Uitsch M., Kossiakoff A.A.;
 RA "Human growth hormone and extracellular domain of its receptor:
 crystal structure of the complex.";
 RL Science 255:306-312(1992).
 RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 19-256.
 RX MEDLINE=97113023; PubMed=8943276;
 RA Sundstrom M., Lundqvist T., Roedin J., Gielia L.B., Milligan D.,
 RA Norstedt G.;
 CC "Crystal structure of an antagonist mutant of human growth hormone,
 RT G120R, in complex with its receptor at 2.9 Å resolution.";
 RL J. Biol. Chem. 271:32197-32203(1996).
 CC "FUNCTION: THIS IS A RECEPTOR FOR PITUITARY GLAND GROWTH HORMONE.
 CC SUBUNIT: HOMODIMER.
 CC SUBCELLULAR LOCATION: Type I membrane protein.
 CC "DISEASE: DEFICIENCY IN GHR IS THE CAUSE OF PITUITARY DWARFISM II
 CC (LARON-TYPE PITUITARY DWARFISM OR LARON SYNDROME (LS)). IT ALSO
 CC CAUSES IDIOPATHIC SHORT STATURE.
 CC "SIMILARITY: BELONGS TO THE CYTOKINE FAMILY OF RECEPTORS.
 CC SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE III-LIKE DOMAIN.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 EMBL X0562; CAA29808.1;
 EMBL M28466; AAA52555.1;
 EMBL M28458; AAA52555.1; JOINED.
 DR EMBL; M28459; AAA52555.1; JOINED.
 DR EMBL; M28460; AAA52555.1; JOINED.
 DR EMBL; M28461; AAA52555.1; JOINED.
 DR EMBL; M28462; AAA52555.1; JOINED.
 DR EMBL; M28463; AAA52555.1; JOINED.
 DR EMBL; M28464; AAA52555.1; JOINED.
 DR EMBL; M28465; AAA52555.1; JOINED.
 DR PIR; A33991; A33991.
 DR PDB; 3NHR; 30 APR-94.
 DR PDB; 1HVG; 19-NOV-97.
 DR PDB; 1HWH; 19-NOV-97.
 DR PDB; 1AXI; 28-JAN-98.
 DR PDB; 2A22; 29-APR-98.
 DR Gene; HGNC:463; GHR.
 DR MIM; 600946; -.
 DR MIM; 26250; -.
 DR InterPro; IPR002996; CRIA.
 DR InterPro; IPR03961; FN_III.
 DR InterPro; IPR03526; Hemtopoptn_L_F1.

DR Pfam; PF00041; fn3; 1.
 DR SMART; SM00050; FN; 1.
 DR PROSITE; PS01152; HEMATOPRO_REC_L_F1; 1.
 KW Receptor; Transmembrane; Glycoprotein; Signal; 3D-structure;
 KW Disease mutation.
 SIGNAL 1 18
 FT CHAIN 19 638
 FT DOMAIN 19 264
 FT TRANSMEM 265 288
 FT DOMAIN 289 638
 FT DOMAIN 145 66
 FT DISULFID 101 56
 FT DISULFID 126 46
 FT CARBOHYD 46 46
 FT CARBOHYD 115 115
 FT CARBOHYD 156 156
 FT CARBOHYD 161 161
 FT CARBOHYD 200 200
 FT VARIANT 62 62
 /FTId=VAR_002708.
 R -> K (IN IDIOPATHIC SHORT STATURE).
 /FTId=VAR_002709.
 R -> K (IN LARON-DWARFISM).
 /FTId=VAR_002710.
 R -> A (IN LARON-DWARFISM).
 /FTId=VAR_002711.
 R -> D (IN LARON-DWARFISM).
 /FTId=VAR_002712.
 R -> S (IN LARON-DWARFISM).
 /FTId=VAR_002713.
 R -> H (IN LARON-DWARFISM; ABOLISH
 RECEPTOR HOMODIMERIZATION).
 /FTId=VAR_002714.
 R -> C (IN LARON-DWARFISM AND IDIOPATHIC
 SHORT STATURE).
 /FTId=VAR_002715.
 R -> G (IN LARON-DWARFISM).
 /FTId=VAR_002716.
 R -> D (IN IDIOPATHIC SHORT STATURE).
 /FTId=VAR_002717.
 R -> L (IN REF. 2).
 FT VARIANT 89 89
 FT VARIANT 114 114
 FT VARIANT 143 143
 FT VARIANT 162 162
 FT VARIANT 170 170
 FT VARIANT 179 179
 FT VARIANT 229 229
 FT VARIANT 242 242
 FT VARIANT 544 544
 FT STRAND 53 58
 FT STRAND 64 68
 FT STRAND 82 88
 FT STRAND 99 100
 FT TURN 104 107
 FT TURN 109 109
 FT STRAND 111 114
 FT TURN 116 117
 FT STRAND 124 124
 FT TURN 132 133
 FT STRAND 134 142
 FT HELIX 143 145
 FT STRAND 147 147
 FT STRAND 153 162
 FT TURN 164 165
 FT STRAND 168 176
 FT TURN 179 180
 FT TURN 183 186
 FT STRAND 190 198
 FT TURN 199 200
 FT STRAND 205 206
 FT STRAND 210 210
 FT STRAND 214 221
 FT TURN 222 223
 FT STRAND 225 234
 FT STRAND 247 250
 SQ SEQUENCE 638 AA; EAFF77EADE4787822 CRC64;
 Query Match 88.4%; Score 38; DB 1; Length 638;
 Best Local Similarity 100.0%; Pred. No. 6;
 Matches 6; Conservative 0; Mismatches 0; Gaps 0;
 Qy 1 CEEFDY 6

Db	259	CEEDFY 264	DT	15-JUL-1999 (Rel. 38. Created)
			DT	15-JUL-1999 (Rel. 38. Last sequence update)
			DT	15-JUL-1999 (Rel. 38. Last annotation update)
			DE	Unknown protein from 2D-page of needles (N147) (Fragments).
RESULT 2			OS	Pinus pinaster (Maritime pine)
GHR_MACMU	STANDARD;	PRT;	OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
ID GHR_MACMU			OC	Spermatophyta; Coniferopsida; Coniferales; Pinaceae; Pinus.
AC P79194;			OC	NCBI_TaxID:71647;
DT 15-JUL-1998 (Rel. 36. Created)			RN	[1]
DT 15-JUL-1998 (Rel. 36. Last sequence update)			RP	SEQUENCE.
DE Growth hormone receptor precursor (GH receptor) (Serum binding protein).			RC	TISSUE-Needle;
GN GHR.			RX	Medline=9974088; PubMed=10344291;
OS Macaca mulatta (Rhesus macaque).			RA	Costa P., Blonneau C., Bauw G., Dubos C., Bahrman N., Kremer A.,
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			RA	Frigerio J.-M., Blonin C.;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopitheciidae;			RT	"Separation and characterization of needle and xylem maritime pine
CC Cercopitheciinae; Macaca.			RT	proteins."
OX NCBI_TaxID:9544;			RL	Electrophoresis 20:1098-1108(1999).
RN			CC	- - MISCELLANEOUS: ON THE 2D-GEL THE DETERMINED PI OF THIS UNKNOWN
SEQUENCE FROM N.A.			CC	PROTEIN IS: 5.6, ITS MW IS: 36 kDa.
RX			FT	NON-TER
Medline=97373601; PubMed=228076;			FT	NON-TER
RA			FT	NON-CONS
Martin J.F., Pezet A., Guenenne C.Y., Edery M., Postel-Vinay M.C.,			FT	11 12
RA			FT	VARIANT 11 13
Kelly P.A.;			FT	VARIANT 13 13
RT			FT	VARIANT 14 14
"Monkey growth hormone (GH) receptor gene expression. Evidence for			FT	VARIANT 15 15
two mechanisms for the generation of the GH binding protein.";			FT	NON-TER 15 15
RL			FT	R -> K.
J. Biol. Chem. 272:18951-18958(1997).			SQ	SEQUENCE 20 AA: 2438 MW: 9F4E4678E088C298 CRC64;
CC	- - FUNCTION: THIS IS A RECEPTOR FOR PITUITARY GLAND GROWTH HORMONE.		Query Match	83.7%;
CC	- - SUBUNIT: HOMODIMER (BY SIMILARITY).		Best Local Similarity	71.4%;
CC	- - SUBCELLULAR LOCATION: TYPE I membrane protein.		Matches	Score 36; DB 1; Length 20;
CC	- - SIMILARITY: BELONGS TO THE CYTOKINE FAMILY OF RECEPTORS.		5; Conservative	Pred. No. 0.43;
CC	- - SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE III-LIKE DOMAIN.		2; Mismatches	0; Indels 0; Gaps 0;
CC	-----		Qy	1 CBEDFYR 7
CC	-----		Db	9 CDKDFYR 15
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation			
CC	at the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (see http://www.isb-sib.ch/announce or send an email to license@isb-sib.ch).			
CC	-----			
DR	U84589; AA847702.1; -.		RESULT 4	
DR	HSSP: P10912; TAXI.		MYCL_HUMAN	STANDARD;
DR	InterPro: IPR003228; Hemiptoptn_L_F1.		TD	MYCL_HUMAN
DR	InterPro: IPR003961; FN_III.		PRT:	364 AA.
DR	InterPro: IPR003228; CRIA.		AC	PI2524; ORNL99;
DR	PROSITE: PS01352; HEMATopo_REC_L_F1.		DT	PI2524; ORNL99; Created
DR	Receptor: Transmembrane; Glycoprotein; Signal.		DT	01-OCT-1989 (Rel. 12. Last sequence update)
DR	POTENTIAL.		DT	01-OCT-1989 (Rel. 12. Last sequence update)
DR	FT SIGNAL 1 18		DT	15-JUN-2002 (Rel. 41. Last annotation update)
DR	CHAIN 19 638		DT	L-myc-1 proto-oncogene protein.
DR	FT DOMAIN 19 264		GN	MYCL OR MYCL OR LMYC.
DR	FT TRANSMEM 265 288		OS	Homo sapiens (Human).
DR	FT DOMAIN 289 638		OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DR	FT DOMAIN 145 252		OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
KW	DISULFID 56 66		OX	NCBI_TaxID:5606;
FT	DISULFID 101 112		RN	[1]
FT	DISULFID 126 140		RN	SEQUENCE FROM N.A.
FT	SEQUENCE 638 AA: 71327 MW: 1F81A55301265F8E CRC64;		RX	Medline=88094386; PubMed=2827002;
Query Match	88.4%;		RA	Kaye F., Battye J., Nau M., Brooks B., Seifert E., de Greve J.,
Best Local Similarity	Score 38; DB 1;		RA	Barter M., Sausville E., Minna J.;
Matches	Length 638;		RT	"Structure and expression of the human L-myc gene reveal a complex
6;	Pred. No. 6;		RT	pattern of alternative mRNA processing."
Best	0;		RT	mol. Cell. Biol. 8:186-195(1988).
Local	Mismatches		RL	[12]
Similarity	0;		RN	SEQUENCE FROM N.A.
	Indels		RX	Medline=88112807; PubMed=3322939;
	0;		RA	DePinho R.A., Hatton K.S., Tesiaye A., Yancopoulos G.D., Alt F.W.:
	0;		RA	"The human myc gene family: structure and activity of L-myc and an
	Indels		RT	L-myc pseudogene."
	0;		RT	Genes Dev. 1:1311-1326(1987).
	Gaps		RL	[13]
	0;		RN	SEQUENCE FROM N.A.
	0;		RA	Ellington A.;
	0;		RL	Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
RESULT 3			CC	- - SUBUNIT: EFFICIENT DNA BINDING REQUIRES DIMERIZATION WITH ANOTHER
UN05_PINPS	STANDARD;	PRT:	CC	BHLH PROTEIN BINDS DNA AS AN HETEROODIMER WITH MAX.
ID UN05_PINPS			CC	- - SIMILARITY: BELONGS TO THE BASIC HELIX-LOOP-HELIX (BHLH) FAMILY OF
AC P81674;			CC	TRANSCRIPTION FACTORS. BHLH-ZIP SUBUNIT.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

<p>This SWISS-PROT entry is copyright. It is produced through a collaboration between the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and thus statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).</p>	
<p>CC or send an email to license@isb-sib.ch.</p>	
EMBL; M19720; AAA59819.1; -;	CC
EMBL; X07262; CAA30248.1; -;	CC
EMBL; X07263; CAA30249.1; -;	CC
PIR; A27675; TVHML.	CC
HSSP; P25912; IHLO.	CC
TRANSFAC; T02385; -;	CC
Gene; HGNC; 75555; MYCL1.	CC
MM; 164850; -;	CC
InterPro; IPR001092; HLH basic.	CC
InterPro; IPR002418; TF_Myc.	CC
Pfam; PF00010; HLH; 1.	CC
Pfam; PF00056; MYC_Nterm; 1.	CC
PRINTS; PR00044; LEUZIPPRMYC.	CC
SMART; SM0353; HLH; 1.	CC
PROSITE; PS00038; HLH_1; 1.	CC
PROSITE; PS50888; HLH_2; 1.	CC
Nuclear protein; DNA-binding; proto-oncogene.	CC
DNA_BIND 294 BASIC DOMAIN.	CC
DOMAIN 295 334 HELIX-LOOP-HELIX MOTIF (BY SIMILARITY).	CC
CONFLICT 333 361 LEUCINE-ZIPPER (POTENTIAL).	CC
CONFLICT 362 362 S -> T (IN REF 3).	CC
SEQUENCE 364 AA; 40312 MW; 58F8A71AC2ED6D4 CRC64;	CC
Query Match 83.7%; Score 36; DB 1; Length 364;	CC
Best Local Similarity 85.7%; Pred. No. 8.3;	CC
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	CC
1 CEDDEFYR 7	CC
1 I I I I I	CC
15 CGEDDEFYR 21	CC
SUUIT 5	CC
CC_MOUSE STANDARD; PRT; 368 AA.	CC
MYCL_MOUSE STANDARD; PRT; 368 AA.	CC
P10166; -;	CC
11-MAR-1989 (Rel. 10, Created)	CC
01-MAR-1989 (Rel. 10, Last sequence update)	CC
30-MAY-2000 (Rel. 39, Last annotation update)	CC
L-myc proto-oncogene protein.	CC
MYCL1 OR MYCL OR LMYC1.	CC
Mus musculus (Mouse).	CC
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	CC
NCBI_TAXID=10090; [1]	CC
SEQUENCE DOMAIN FROM N.A.	CC
STRAIN=BALB/C; MEDLINE=98111523; PubMed=2828024;	CC
Legouy E., Depinho R.A., Zimmerman K., Collum R., Yancopoulos G.D., Milescock L., Krieg L., Alt F.W.; <i>Alt F.W.</i>	CC
Structure and expression of the murine L-myc gene.";	CC
EMBO J. 6:3359-3366(1987).	CC
-!- SUBUNIT: EFFICIENT DNA BINDING REQUIRES DIMERIZATION WITH ANOTHER BHLH PROTEIN. BINDS DNA AS AN HETERODIMER WITH MAX.	CC
-!- SIMILARITY: BELONGS TO THE BASIC HELIX-LOOP-HELIX (BHLH) FAMILY OF TRANSCRIPTION FACTORS. BHLH-ZIP SUBFAMILY.	CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).	CC
DR EMBL; AJ277915; CAB97493.1; -;	CC
DR EMBL; AJ277916; CAB981128.1; ALT_SEQ.	CC
DR EMBL; AJ277917; CAB981128.1; JOINED.	CC
DR EMBL; AJ277918; CAB981128.1; JOINED.	CC
DR EMBL; AJ277919; CAB981128.1; JOINED.	CC
DR EMBL; AJ277920; CAB981128.1; JOINED.	CC
DR EMBL; AJ27862722; CAB981317A;	CC

Qy	1	CEEDFYR 7	Best Local Similarity 71.4%;	Pred. No. 9.7;	
Db	102	CKEDYR 108	Matches 5; Conservative 2;	Mismatches 0; Indels 0; Gaps	
RESULT 10					
LHX2_RAT	ID	LHX2_RAT	STANDARD;	PRT;	426 AA.
AC	P36198;				
DT	01-JUN-1994	(Rel. 29, Created)			
DT	01-JUN-1994	(Rel. 29, Last sequence update)			
DT	15-JUN-2002	(Rel. 41, Last annotation update)			
DE	LIM/homeobox protein Lhx2 (Homeobox protein Lh-2).				
GN	LHX2 OR LH2.				
OS	Rattus norvegicus (Rat).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus. NCBI_TAXID=10116;				
XX					
XX	[11]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Brain;				
RX	Medline=93126348; PubMed=7678338;				
RA	Yancopoulos G.D., Jessell T.M., Alt F.W.; "Lh-2: a LIM/homeobox gene expressed in developing lymphocytes and neural cells."				
RT	Proc. Natl. Acad. Sci. U.S.A. 90:227-231 (1993).				
CC	-.- FUNCTION: TRANSCRIPTIONAL REGULATORY PROTEIN INVOLVED IN THE CONTROL OF CELL DIFFERENTIATION IN DEVELOPING LYMPHOID AND NEURAL CELL TYPES.				
CC	-.- SUBCELLULAR LOCATION: Nuclear (Probable).				
CC	-.- TISSUE SPECIFICITY: FOUND IN DISCRETE REGIONS OF THE DEVELOPING CNS, PRIMARILY IN Diencephalic AND TELENCEPHALIC STRUCTURES AND A SUBSET OF LYMPHOID TISSUES. ALSO FOUND IN EMBRYONIC SPINAL CHORD AND FETAL LIVER.				
CC	-.- DEVELOPMENTAL STAGE: EXPRESSED IN DEVELOPING LYMPHOCYTES AND NEURAL CELLS. MAXIMAL EXPRESSION IS FOUND IN PRE-B-LYMPHOCYTES.				
CC	-.- SIMILARITY: CONTAINS 1 HOMEBOX DOMAIN.				
CC	-.- SIMILARITY: CONTAINS 2 LIM DOMAINS. THE LIM DOMAIN BINDS 2 ZINC IONS.				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).				
CC	-----				
DR	EMBL: L06804; :- NOT_ANNOTATED_CDS.				
DR	HSBPL: P06601; IFLU.				
DR	TRANSFAC: T01966; :-				
DR	InterPro: IPR01356; Homeobox.				
DR	InterPro: IPR01781; LIM.				
DR	Pfam: PF00046; homeobox; 1.				
DR	Pfam: PF00412; LIM; 2.				
DR	ProDom: PD000010; Homeobox; 1.				
DR	ProDom: PD000094; LIM; 2.				
DR	SMART: SM00389; HOX; 1.				
DR	SMART: SM00132; LIM; 2.				
DR	PROSITE: PS00027; HOMEBOX; 1.				
DR	PROSITE: PS00078; LIM_DOMAIN_1; 2.				
DR	PROSITE: PS00023; LIM_DOMAIN_2; 2.				
DR	PROSITE: PS00071; HOMEBOX; 2; 1.				
KW	Homeobox; DNA-binding; Nuclear protein; Repeat; LIM domain; Metal-binding; Zinc; Transcription regulation.				
FT	DOMAIN 52: 104 LIM 1.				
FT	DOMAIN 114: 167 LIM 2.				
FT	DNA-BIND 264 323 HOMEBOX.				
FT	DNA-BIND 305 321 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).				
SQ	SEQUENCE 426 AA: 47418 MW; DC8FA3DB4572B40 CRC64;				
CC	83.7% Score 36; DB 1; Length 426;				

DR PROSITE; PS50119; ZF_BBOX; 2. Repeat; Multigene family.
 KW Zinc-finger; Nuclear protein; B-BOX-TYPE 1.
 FT ZN_FING 5 47 B-BOX-TYPE 2 (ATOPICAL).
 FT ZN_FING 48 99 B-BOX-TYPE 2 (ATOPICAL).
 FT DOMAIN 77 83 POLY-ASN.
 FT DOMAIN 84 90 POLY-ASN.
 SQ SEQUENCE 372 AA; 40754 MW; 188F18BB283D7479 CRC64;

Query Match 81.4%; Score 35; DB 1; Length 372;
 Best Local Similarity 83.3%; Pred. No. 13;
 Matches 5; Conservative 1; Mismatches 0; Gaps 0;
 QY 1 CEEFDY 6
 Db 181 CEDDY 186

RESULT 12
 BAL_MOUSE ID BAL_MOUSE STANDARD; PRT; 599 AA.
 AC Q64385;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DE 30-MAY-2000 (Rel. 39, Last annotation update)
 DE Bile-salt-activated lipase precursor (EC 3.1.1.3) (BAL)
 DE (Bile-salt-activated lipase) (BSAL) (Carboxy ester lipase) (Sterol
 esterase) (Cholesterol esterase) (Pancreatic lysophospholipase).
 DE CEL OR LIP1.
 OC Mus musculus (Mouse).
 OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Murinae; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c; TISSUE=Mammary gland;
 RX MEDLINE=3609631; PubMed=8522186;
 RA Mackay K, Laven R, M;
 RA "Characterization of the mouse pancreatic/mammary gland cholesterol
 esterase-encoding cDNA and gene.";
 RT esterase-encoding cDNA and gene.;
 RT Gene 165:255-259 (1995).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c; TISSUE=Lactating mammary gland;
 RX MEDLINE=36079098; PubMed=8530060;
 RA Lidner A.-S., Kannius M., Lundberg L., Bjursell G., Nilsson J.;
 RT "Molecular cloning and characterization of the mouse carboxyl ester
 lipase gene and evidence for expression in the lactating mammary
 gland.";
 RL Genomics 29:115-122(1995).
 CC -!- FUNCTION: CATALYZES FAT AND VITAMIN ABSORPTION. ACTS IN CONCERT
 WITH PANCREATIC LIPASE AND COLIPASE FOR THE COMPLETE DIGESTION
 OF DIETARY TRIGLYCERIDES (BY SIMILARITY).
 CC -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
 fatty acid anion.
 CC -!- CATALYTIC ACTIVITY: A sterol ester + H(2)O = a sterol + a fatty
 acid.
 CC -!- SIMILARITY: BELONGS TO THE TYPE-B CARBOXYLESTERASE/LIPASE FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions. There are no restrictions on its
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AAA92088; 1;
 DR EMBL; U37386; ANC52279; 1;
 DR HSSP; P30122; 2BCE.
 DR MGD; MGI-88374; Cel.
 DR InterPro; IPR002018; carboxylesterase.
 DR InterPro; IPR000379; Ser_enzrs_site.

DR PROSITE; PS00122; CARBOXYLESTERASE_B_2; 1.
 DR PROSITE; PS00941; CARBOXYLESTERASE_B_2; 1.
 KW Hydrolase; Serine esterase; Lipid degradation; Glycoprotein;
 KW Repeat; Signal.

FT SIGNAL 1 20 BY SIMILARITY.
 FT CHAIN 21 599 BY BILE-SALT-ACTIVATED LIPASE.
 FT ACT_SITE 214 340 BY SIMILARITY.
 FT ACT_SITE 214 340 BY SIMILARITY.
 FT ACT_SITE 214 340 BY SIMILARITY.
 FT DISULFID 84 100 BY SIMILARITY.
 FT DISULFID 266 277 BY SIMILARITY.
 FT DOMAIN 559 588 4 X 11 AA TANDEM REPEATS, O-GLYCOSYLATED
 REGION.
 FT REPEAT 559 569 1.
 FT REPEAT 570 580 2.
 FT REPEAT 581 588 3.
 FT CARBOHYD 207 207 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 325 325 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 599 AA; 65813 MW; 9E4428FDFA8602E CRC64;

Query Match 79.1%; Score 34; DB 1; Length 599;
 Best Local Similarity 100.0%; Pred. No. 33;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 EEDFYR 7
 Db 361 EEDFYR 366

RESULT 13
 BAL_RAT ID BAL_RAT STANDARD; PRT; 612 AA.
 AC P07882; P14722;
 AC P07882; P14722;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 01-OCT-1996 (Rel. 34, Last annotation update)
 DE Bile-salt-activated lipase precursor (EC 3.1.1.3) (BAL)
 DE (Bile-salt-stimulated lipase) (BSSL) (Carboxy ester lipase) (Sterol
 esterase) (Cholesterol esterase) (Pancreatic lysophospholipase).
 DE (Bile-salt-stimulated lipase) (BSSL) (Carboxy ester lipase) (Sterol
 esterase) (Cholesterol esterase) (Pancreatic lysophospholipase).
 GN CEL.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OC NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sprague-Dawley; TISSUE=Pancreas;
 RX MEDLINE=90083378; PubMed=2688744;
 RA Kissel J.A., Pontaine R.N., Turk C.W., Brockman H.L., Hui D.Y.;
 RT "Molecular cloning and expression of cDNA for rat pancreatic
 RT cholesterol esterase";
 RT "Isolation of full-length putative rat lysophospholipase cDNA using
 RT improved methods for mRNA isolation and cDNA cloning.";
 RT Biochemistry 26:1617-1625(1987).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=8724339; PubMed=3593682;
 RX MEDLINE=9129758; PubMed=2069957;
 RA Fontaine R.N., Carter C.P., Hui D.Y.;
 RT "Structure of the rat pancreatic cholesterol esterase gene.";
 RT Biochemistry 30:7008-7014(1991).
 RN [4]
 RP ACTIVE SITE SER-214.
 RX MEDLINE=11003095; PubMed=2211595;
 RA DiPersio L.P., Fontaine R.N., Hui D.Y.;
 RT "Identification of the active site serine in pancreatic cholesterol
 RT esterase by chemical modification and site-specific mutagenesis.";
 RL J. Biol. Chem. 265:16801-16806(1990).

RN	[5]	11111	Db	361	EEDFYR	366
RP	ACTIVE SITE HIS-455.					
RX	PubMed=91154187;					
RA	Dipersio L.P., Fontaine R.N., Hui D.Y.;					
RT	Site specific mutagenesis of an essential histidine residue in					
RT	pancreatic cholesterol esterase.;"					
RL	"Site specific mutagenesis of an essential histidine residue in					
CC	pancreatic cholesterol esterase.;"					
CC	-!- FUNCTION: CATALYZES FAT AND VITAMIN ABSORPTION. ACTS IN CONCERT					
CC	WITH PANCREATIC LIPASE AND COLPOASE FOR THE COMPLETE DIGESTION					
CC	OF DIETARY TRIGLYCERIDES.					
CC	-!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a					
CC	fatty acid anion.					
CC	-!- CATALYTIC ACTIVITY: A sterol ester + H(2)O = a sterol + a fatty					
CC	acid.					
CC	-!- ENZYME REGULATION: ACTIVATED BY BILE SALTS CONTAINING A 7-HYDROXYL					
CC	GROUP.					
CC	-!- TISSUE SPECIFICITY: SYNTHESIZED PRIMARILY IN THE PANCREAS AND THEN					
CC	TRANSPORTED TO THE INTESTINE.					
CC	-!- SIMILARITY: BELONGS TO THE TYPE-B CARBOXYL ESTERASE/LIPASE FAMILY.					
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration					
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -					
CC	the European Bioinformatics Institute. There are no restrictions on its					
CC	use by non-profit institutions as long as its content is in no way					
CC	modified and this statement is not removed. Usage by and for commercial					
CC	entities requires a license agreement (see http://www.isb-sib.ch/announce/					
CC	or send an email to license@ish-sib.ch).					
CC	CC					
DR	EMBL; X16054; CAA34189.1.					
DR	EMBL; M15853; AAA4150.1.					
DR	EMBL; M69157; AAB46376.1.					
DR	PIR; A34967; A34967.					
DR	PIR; A26603; A26603.					
DR	HSSP; P30122; 2BCE.					
DR	InterPro; IPR002018; CarboxylesteraseB.					
DR	InterPro; IPR003079; Ser.estrs_site.					
DR	Pfam; PF00135; Coesterase_1.					
DR	PROSITE; PS00122; CARBOXYL ESTERASE_B-1; 1.					
DR	PROSITE; PS00121; CARBOXYL ESTERASE_B-2; 1.					
KW	Hydrolyase; Serine esterase; Lipid degradation; Glycoprotein;					
KW	Repeat; Signal	1	20			
FT	CHAIN	21	612	BILE-SALT-ACTIVATED LIPASE.		
FT	ACT_SITE	214	214	BY SIMILARITY.		
FT	ACT_SITE	340	340	BY SIMILARITY.		
FT	ACT_SITE	455	455	BY SIMILARITY.		
FT	DISULFID	84	100	BY SIMILARITY.		
FT	DISULFID	266	277	BY SIMILARITY.		
FT	CARBONYD	207	207	N-LINED (GLCNAC. . .) (POTENTIAL).		
FT	DOMAIN	556	599	4 X 11 AA TANDEM REPEATS, O-GLYCOSYLATED		
FT	REPEAT	556	566	REGION.		
FT	REPEAT	567	577	1.		
FT	REPEAT	578	588	.		
FT	REPEAT	589	599	.		
FT	MUTAGEN	440	440	H->Q; NO EFFECT ON ACTIVITY.		
FT	MUTAGEN	455	455	H->Q; R,A,S,D; ABOLISH ACTIVITY.		
FT	CONFLICT	26	26	V -> L (IN REF. 2).		
FT	CONFLICT	154	154	G -> A (IN REF. 2).		
FT	CONFLICT	217	217	A -> G (IN REF. 2).		
FT	CONFLICT	219	219	S -> I (IN REF. 2).		
FT	CONFLICT	419	419	M -> T (IN REF. 3).		
FT	CONFLICT	513	513	T -> M (IN REF. 2 AND 3).		
FT	CONFLICT	576	577	GG -> VV (IN REF. 3).		
FT	CONFLICT	608	609	GP -> VV (IN REF. 3).		
FT	CONFLICT	611	611	G -> A (IN REF. 3).		
SQ	SEQUENCE	612	AA;	67040 MW;	1565CE4EA71ED02A CRC64;	
Query Match		79.1%	Score 34; DB 1;	Length 612;		
Best Local Similarity	100.0%	Pred. No. 34;	Indels 0;	Gaps 0;		
Matches	6;	Conservative 0;	Mismatches 0;			
Qy	2 EEDFYR 7					
Db	425 EEDFYR 430					
Query Match		79.1%	Score 34; DB 1;	Length 612;		
Best Local Similarity	100.0%	Pred. No. 34;	Indels 0;	Gaps 0;		
Matches	6;	Conservative 0;	Mismatches 0;			
Qy	2 EEDFYR 7					
Db	425 EEDFYR 430					
RESULT	15					
Y576_ARCFU						
ID	Y576_ARCFU					
AC	029679;					
STANDARD						
PRT						
86 AA.						

DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Hypothetical protein AF0576.
 GN AF0576.
 OS Archaeoglobus fulgidus.
 OC Archaea; Euryarchaeota; Archaeoglobi; Archaeoglobales;
 OC Archaeoglobaceae; Archaeoglobus.
 OX NCBL.TaxID=2234;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX STRAIN=VC-16 / DSM 4304 / ATCC 49558;
 RX MEDLINE=58049343; PubMed=9389475;
 RA Klein H.P., Clayton R.A., Tomb J.-F., White O., Nelson K.E.,
 RA Ketchum K.A., Dodson R.J., Gwinn M., Hickey E.K., Peterson J.D.,
 RA Richardson D.L., Kerlavage A.R., Graham D.E., Myrvidis N.C.,
 RA Fleischmann R.D., Quackenbush J., Lee N.H., Sutton G.G., Gill S.,
 RA Kirkness E.F., Dougherty B.A., McKenney K., Adams M.D., Loftus B.,
 RA Peterson S., Reich C.I., McNeil L.K., Badger J.H., Glodek A., Zhou L.,
 RA Overbeek R., Gocayne J.D., Weidman J.P., McDonald L., Utterback T.,
 RA Cotton M.D., Spriggs T., Artiach P., Kaine B.P., Styles S.M.,
 RA Sadow P.W., D'Andrea K.P., Bowman C., Fujii C., Garland S.A.,
 RA Mason T.M., Olsen G.J., Fraser C.M., Smith H.O., Woese C.R.,
 RA Venter J.C.;
 RT "The complete genome sequence of the hyperthermophilic, sulphate-
 reducing archaeon *Archaeoglobus fulgidus*."
 RL Nature 390:364-370 (1997).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AE00105; AAB09075.1; -.
 DR TIGR; AF0576; -.
 KW Hypothetical protein; Complete proteome.
 SQ SEQUENCE 86 AA; 10018 MW; 03AA3D19DAB8000C CRC64;
 Query Match 76.7%; Score 33; DB 1; Length 86;
 Best Local Similarity 71.4%; Pred. No. 7.1;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 CEEFYR 7
 |||:
 Db 67 CEEFYR 73

Search completed: February 12, 2003, 11:44:59
 time : 7.53333 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 12, 2003, 11:42:45 ; Search time 52.7333 Seconds
(without alignments)
27.351 Million cell updates/sec

Title: US-09-660-302c-7
Perfect score: 43
Sequence: 1 CEDDFYR 7

Scoring table: BLOSUM62
Gapp 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08
Maximum Match 100%
Listing first 45 summaries

Database : SPRTRMBL.21:*

1: sp_archaea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mhc:*

8: sp_organelle:*

9: sp_phage:*

10: sp_plant:*

11: sp Rodent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unguided:*

15: sp_rvirus:*

16: sp_bacteriaph:*

17: sp_archaea:*

1: sp_archaea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mhc:*

8: sp_organelle:*

9: sp_phage:*

10: sp_plant:*

11: sp_Rodent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unguided:*

15: sp_rvirus:*

16: sp_bacteriaph:*

17: sp_archaea:*

17 35 81.4 552 16 Q8zg66 salmonella
18 35 81.4 552 16 Q8zg67 salmonella
19 35 81.4 1376 5 Q26637 strongyloete
20 35 81.4 1823 5 Q26638 paracentrot
21 35 81.4 3198 5 Q26639 strongyloete
22 34 79.1 262 5 Q8suq6 encephalito
23 34 79.1 277 10 Q9sk11 arabidopsis
24 34 79.1 331 16 Q97id4 clostridium
25 34 79.1 420 16 Q8ra45 thermococcus
26 34 79.1 563 16 Q8vn67 anabaena sp
27 34 79.1 592 11 Q64571 rattus norve
28 34 79.1 599 11 Q922r3 mus musculus
29 34 79.1 625 3 Q94300 schizosaccharomyces
30 34 79.1 639 11 Q63202 rattus norve
31 34 79.1 1037 12 Q9QH62 gallid herpes
32 33 76.7 98 5 Q16939 ancylostoma
33 33 76.7 156 4 Q9w4q9 drosophila
34 33 76.7 243 5 Q95x85 caenorhabditis
35 33 76.7 272 16 Q98pn8 mycoplasma
36 33 76.7 441 5 Q9yyv12 melanoplus
37 33 76.7 496 5 Q45368 caenorhabditis
38 32 74.4 60 4 Q96jp7 homo sapiens
39 32 74.4 200 4 Q9ufd6
40 32 74.4 213 10 Q9fp18 oryza sativa
41 32 74.4 214 13 Q8uvd2 gallus gallus
42 32 74.4 226 17 Q8zwu1 pyrobaculum
43 32 74.4 249 16 Q97tp4 clostridium
44 32 74.4 267 5 Q90673 artemia salina
45 32 74.4 272 5 Q8wtm7 cotesia kar
Q8wtm7

ALIGNMENTS

RESULT 1
Q8R8G6
ID Q8R8G6
AC Q8R8G6;
DT 01-JUN-2002 (TREMBLref. 21, Created)
DT 01-JUN-2002 (TREMBLref. 21, Last sequence update)
DT 01-JUN-2002 (TREMBLref. 21, Last annotation update)
DE Hypothetical protein TTE2033.
GN TTE2033.
OS Thermoanaerobacter tengcongensis.
OC Bacteria: Firmicutes: Bacillus/Clostridium group; Clostridia;
OC Thermoanaerobacteriales; Thermoanaerobacteraceae; Thermoanaerobacter.
OX NCBI_TAXID=119072;
RN [11]
RP SEQUENCE FROM N.A.
RC STRAIN=MBAT / JCM11007;
RC MEDLINE=21992816; PubMed=11997336;
RA Bao Q., Tian Y., Li W., Xu Z., Xuan Z., Hu S., Dong W., Yang J.,
RA Chen Y., Xue Y., Xu Y., Lai X., Huang L., Dong X., Ma Y., Ling L.,
RA Tan H., Chen R., Wang J., Yu J., Yang H.;
RT "A complete sequence of *T. tengcongensis* genome.";
RL Genome Res. 12:689-700 (2002).
DR EAO13153; AAH25210.1; -
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 153 AA; 18428 MW;

SUMMARIES

RESULTS

Query Score Match Length DB ID Description
No. No. No. No. No. No.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

DT 01-DEC-2001 (TREMBLrel. 19, Created)
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
 DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
 DE Growth hormone receptor.
 OS *Salimir bolliviensis* (Bolivian squirrel monkey).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Piatyrhini; Cebidae; Cebinae; Saimiri.
 NCBI_TaxID=27679;
 RN [1]
 RP SEQUENCE FROM N.A.; PubMed=11371582;
 RA Liu J.C.; Makova K.D.; Adkars R.M.; Gibson S.; Li W.H.;
 RT "Episodic Evolution of Growth Hormone in Primates and Emergence of the Species Specificity of Human Growth Hormone Receptor.";
 RL Mol. Biol. Evol. 18: 945-953 (2001).
 DR AF330651; AAK62288.1; -.
 DR InterPro: IPR002996; CRLA.
 DR InterPro: IPR003961; FN_III.
 DR Pfam: PF00041; fn3; 1.
 SMART; SM00060; FN3; 1.
 DR Receptor; PS01352; HEMATOPO_REC_L_F1; UNKNOWN_1.
 SEQUENCE 632 AA; 70883 MW; 440E17AF627EDA3 CRC64;
 Query Match 88.4%; Score 38; DB 6; Length 632;
 Best Local Similarity 100.0%; Pred. No. 21;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 CEEDEFY 6
 DR 259 CEEDEFY 264

RESULT 3
 Q9ASZ1 PRELIMINARY; PRT; 638 AA.
 ID Q9ASZ1;
 AC Q9ASZ1;
 DT 01-NOV-1999 (TREMBLrel. 12, Created)
 DT 01-MAR-1999 (TREMBLrel. 12, Last sequence update)
 DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
 DE Growth hormone receptor.
 OS *Papio anubis* (Olive baboon).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopithecinae; Papio.
 NCBI_TaxID=9555;
 RN [1]
 RP SEQUENCE FROM N.A.; PubMed=10425448;
 RA Zegopoulos G.; Nathanielsz P.; Hendy G.N.; Goodyer C.G.;
 RT "The baboon: a model for the study of primate growth hormone receptor gene expression during development.";
 RL J. Mol. Endocrinol. 23:67-75(1999).
 DR HSSP; P10912; IAXI.
 DR InterPro: IPR002996; CRLA.
 DR InterPro: IPR0361; FN_III.
 DR Pfam: PF00041; fn3; 1.
 SMART; SM00060; FN3; 1.
 PROSITE; PS01352; HEMATOPO_REC_L_F1; UNKNOWN_1.
 KW Receptor.
 SQ SEQUENCE 638 AA; 71407 MW; 9E250C8E303E420 CRC64;
 Query Match 88.4%; Score 38; DB 6; Length 638;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 4
 Q9QY66 PRELIMINARY; PRT; 399 AA.
 ID Q9QY66;
 AC Q9QY66;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
 DE C1orf5.
 GN ORF6.
 OS *Mus musculus* (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.; MEDLINE=20065078; PubMed=10602999;
 RX Lemmens I.H.; Farnebo F.; Piehl F.; Merregaert J.; Van de Ven W.J.M.; Larsson C.; Kas K.;
 RA "Molecular characterization of human and murine cllorf5, a new member of the FAUNA gene cluster.";
 RT RL Mamm. Genome 11:78-80(2000).
 DR EMBL; AF119498; AAF235021; -.
 DR MGDB; MG1:1354481; ORF6.
 SQ SEQUENCE 399 AA; 43038 MW; 6BED852632747B54 CRC64;
 Query Match 86.0%; Score 37; DB 11; Length 399;
 Best Local Similarity 85.7%; Pred. No. 21;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 5
 Q8VCQ7 PRELIMINARY; PRT; 399 AA.
 ID Q8VCQ7;
 AC Q8VCQ7;
 DT 01-MAR-2002 (TREMBLrel. 20, Created)
 DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
 DE Open reading frame 6.
 OS *Mus musculus* (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.; RC TISSUE-LIVER;
 RA Strausberg R.;
 RT Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC019440; AAH19440.1; -.
 SQ SEQUENCE 399 AA; 42995 MW; B5CA88342B56932B CRC64;
 Query Match 86.0%; Score 37; DB 11; Length 399;
 Best Local Similarity 85.7%; Pred. No. 21;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 6
 Q9U9B1 PRELIMINARY; PRT; 76 AA.
 ID Q9U9B1;
 AC Q9U9B1;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DE Ascaris type serine protease inhibitor (Fragment).
 OS *Ascaris ceylanicum*.

OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Strongylida;
 OC Ancylostomatidae; Ancylostomatidae; Ancylostoma; Ancylostoma.
 OC NCBI_TaxID=53326;

RN [1]

RP SEQUENCE FROM N.A.

RA Harrison L.M., Cappello M.;
 RT "The molecular cloning of an ascaris type serine protease inhibitor
 from adult Ancylostoma ceylanicum hookworms.";
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.

DR EMBL: AF172653; AAD61336.1; -.

DR HSSP: P56682; 1CCV.

DR InterPro: IPR000561; EGF-like.

DR InterPro: IPR002919; TIL_Cysrich.

DR InterPro: PF01826; TIL; 1.

DR PROSITE: PS01186; EGF_2; UNKNOWN_1.

KW Protease.

FT SEQUENCE 76 AA; 8385 MW; D35FCFF7C2088A53 CRC64;

QY 1 CEEDFYR 7

DB 44 CEEGFYR 50

Query Match 83.7%; Score 36; DB 5; Length 76;
 Best Local Similarity 85.7%; Pred. No. 6.1; Indels 0; Gaps 0;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULTS 7

Q16938 ID Q16938 PRELIMINARY; PRT; 91 AA.

AC Q16938;

DT 01-NOV-1996 (TREMBLrel. 01; Created)

DT 01-NOV-1996 (TREMBLrel. 01; Last sequence update)

DT 01-JUN-2002 (TREMBLrel. 21; Last annotation update)

DE Anti-coagulant protein C2 precursor (Fragment).

OS Ancylostoma caninum (Dog hookworm).

OC Eukaryota; Metazoa; Chromadorea; Rhabditida; Strongylida;
 Ancylostomatidae; Ancylostomatidae; Ancylostoma; Ancylostoma.

OX NCBI_TaxID=29170;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=98298519; PubMed=9634780;

RA Jespers L.S., Messens J.H., De Keyser A., Beckhout D.,
 van den Brande I., Gansmeiers Y.G., Lauwereys M.J., Vlaesuk G.P.,
 Stanssens P.E.,

RA Lasters I., Vlaesuk G.P.;

RA "Anticoagulant repertoire of the hookworm Ancylostoma caninum.";
 RL Proc. Natl. Acad. Sci. U.S.A. 93:2149-2154 (1996).

DR EMBL: U30791; AAC47080.1; -.

DR HSSP: P56682; 1CCV.

DR InterPro: IPR000561; EGF-like.

DR InterPro: IPR002919; TIL_Cysrich.

DR InterPro: PF01826; TIL; 1.

DR PROSITE: PS01186; EGF_2; UNKNOWN_1.

KW Signal.

FT NON-TER 1 1

FT SIGNAL <1 7

FT CHAIN 8 91

SEQUENCE 91 AA; 10358 MW; ECB1ICB4597C24DA CRC64;

Query Match 83.7%; Score 36; DB 5; Length 91;
 Best Local Similarity 85.7%; Pred. No. 7.3; Indels 1; Mismatches 0; Gaps 0;

RESULTS 8

Q98SF6 ID Q98SF6 PRELIMINARY; PRT; 125 AA.

AC Q98SF6;

DT 01-JUN-2001 (TREMBLrel. 17; Created)

DT 01-JUN-2001 (TREMBLrel. 17; Last sequence update)

DT 01-DEC-2001 (TREMBLrel. 19; Last annotation update)

DE Lhx2 protein (Fragment).

GN Lhx2.

OS Xenopus laevis (African clawed frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Xenopus.

OC Xenopodinae; Xenopus.

OX NCBI_TaxID=8355;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE-HEAD;

RA Bachy I., Vernier P., Retaux S.;

RT "The LIM-homeodomain family in the developing xenopus brain:
 conservation and divergences with the mouse related to the evolution
 of the forebrain.";

RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.

CC -!- SIMILARITY: CONTAINS 2 LIM DOMAINS. THE LIM DOMAIN BINDS 2 ZINC
 IONS.

DR AJ311712; CAC35215.1; -.

DR P32965; 1CPL.

DR InterPro: IPR001781; LIM.

DR PF00412; LIM; 2.

DR PRODOM; PD000094; LIM; 1.

DR SMART; SM00132; LIM; 2.

DR PROSITE; PS00478; LIM_DOMAIN_1; 1.

DR PROSITE; PS50023; LIM_DOMAIN_2; 2.

KW LIM domain; Metal-binding; Zinc.

FT NON-TER 1 1

FT NON-TER 125 125

SQ SEQUENCE 125 AA; 14283 MW; 375E42A29104D364 CRC64;

Query Match 83.7%; Score 36; DB 13; Length 125;
 Best Local Similarity 71.4%; Pred. No. 10; Indels 0; Gaps 0;
 Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 CEEDFYR 7

DB 28 CKEDYR 34

RESULTS 9

Q14897 ID Q14897 PRELIMINARY; PRT; 206 AA.

AC Q14897;

DT 01-NOV-1996 (TREMBLrel. 01; Created)

DT 01-NOV-1996 (TREMBLrel. 01; Last sequence update)

DT 01-JUN-2002 (TREMBLrel. 21; Last annotation update)

DE L-myc protein (Similar to lung carcinoma myc related oncogene 1).

GN L-MYC.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE-PLACENTA;

RX MEDLINE=8804386; PubMed=2827002;

RA Raye F., Battye J., Nau M., Brooks B., Seifert E., De Greve J.,
 Birrer M., Sausville E., Minna J.;

RT "Structure and expression of the human L-myc gene reveal a complex
 pattern of alternative mRNA processing.";

RL Mol. Cell. Biol. 8:186-195(1988).

RN	[2]	SEQUENCE FROM N.A.	PRT;	297 AA.
RP	SEQUENCE=PLACENTA;			
RC	TISSUE=;			
RA	Strausberg R.			
RA	Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.			
RL	EMBL; M19720; AAAS98:8.1;			
DR	EMBL; BC011864; AAH11864.1;			
DR	TRANSFAC; T02306;			
DR	InterPro; IPR002418;			
DR	PFam; PF01056; MYC_N term; 1;			
DR	SEQUENCE 206 AA;	585c9CD6c9A8EC71 CRC64;		
Query Match	83.7%	Score 36; DB 4; Length 206;		
Best Local Similarity	85.7%	Pred. No. 17;		
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
Qy	1 CEEDEFYR 7	PRELIMINARY;	PRT;	217 AA.
Db	1 I I I I	01-JUN-2001 (TREMBLrel. 17, Created)		
Db	15 CGEDFYR 21	01-JUN-2001 (TREMBLrel. 17, Last sequence update)		
Db	DE Lhx9 protein (Fragment).	01-MAR-2002 (TREMBLrel. 20, Last annotation update)		
CC	-! SIMILARITY: CONTAINS 1 LIM DOMAIN. THE LIM DOMAIN BINDS 2 ZINC LIONS			
CC	EMBL; AJ311711; CAC35214.1;			
CC	DR InterPro; IPR001356; Homeobox.			
CC	DR InterPro; IPR001781; LIM.			
CC	DR PF00046; homeobox; 1.			
CC	DR PF00412; LIM; 2.			
CC	DR ProDom; PD000010; Homeobox; 1.			
CC	DR SMART; SM00389; LIM; 2.			
CC	DR SMART; SM00132; LIM; 1.			
CC	DR PROSITE; PS50071; HOMEBOX; 2; 1.			
CC	DR PROSITE; PS00478; LIM_DOMAIN; 1; 1.			
CC	DR PROSITE; PS50023; LIM_DOMAIN; 2; 2.			
CC	KW LIM domain; Metal-binding; Zinc.			
CC	FT NON_TER 1 1			
CC	FT 217 217 AA; 24716 MW; 6CBEB8B595ECBB851 CRC64;			
Query Match	83.7%	Score 36; DB 13; Length 217;		
Best Local Similarity	71.4%	Pred. No. 18;		
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;				
Qy	1 CEEDEFYR 7	PRELIMINARY;	PRT;	378 AA.
Db	1 : I : I : I	01-NOV-1996 (TREMBLrel. 01, Created)		
Db	27 CKEDYR 33	01-MAR-2002 (TREMBLrel. 20, Last annotation update)		
RESULT 11	Q9CSG0	Homeobox protein.		
RESULT 12	Q90881			
	ID Q90881	PRELIMINARY;	PRT;	378 AA.
	AC Q90881			
	DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)			
	DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)			
	DE LIM DOMAIN BINDS 2 ZINC LIONS			
	DR EMBL; AK012930; BAB28555.1; -.			
	DR HSSP; P32965; 1CTL.			
	DR MGII; MGI-1316721; Lhx9.			
	DR InterPro; IPR001356; Homeobox.			
	DR InterPro; IPR001781; LIM.			
	DR Pfam; PF00046; homeobox; 1.			
	DR Pfam; PF00412; LIM; 2.			
	DR ProDom; PD000010; Homeobox; 1.			
	DR ProDom; PD00094; LIM; 2.			
	DR SMART; SM00389; HOX; 1.			
	DR SMART; SM00132; LIM; 2.			
	DR PROSITE; PS50071; HOMEBOX; 2; 1.			
	DR PROSITE; PS00478; LIM_DOMAIN; 1; 1.			
	DR PROSITE; PS50023; LIM_DOMAIN; 2; 2.			
	KW LIM domain; Metal-binding; Zinc.			
	FT NON_TER 1 1			
	FT 33502 MW; 3040FE3B819BB053 CRC64;			
	FT 297 AA;			
	Query Match 83.7%; Score 36; DB 11; Length 297;			
	Best Local Similarity 71.4%; Pred. No. 25;			
	Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;			
Qy	1 CEEDEFYR 7	PRELIMINARY;	PRT;	378 AA.
Db	87 CKEDYR 93			

OS	Gallus gallus (Chicken).	DR	InterPro; IPR001781; LIM.
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	DR	PFam; PF00046; homeobox; 1.
OC	Archosauia; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;	DR	PFam; PF00042; LIM; 2.
OC	Gallus.	DR	PFam; PF00040; Homeobox; 1.
NCBI_TAXID=9031;		DR	PFam; PF00049; LIM; 2.
OX	[1]	DR	PFam; PF00094; LIM; 2.
RP	SEQUENCE FROM N. A.	DR	SMART; SM00389; HOX; 1.
RC	TISSUE-BRAIN;	DR	SMART; SM00132; LIM; 2.
RA	Tremml G., Jessell T. M.;	DR	PROSITE; PS00027; HOMEOBOX-1; 1.
RT	"Differentiation of dorsal commissural neurons defined by expression of the LIM homeobox gene Lh-2: suppression by notochord grafts and maintained after notochord removal".	DR	PROSITE; PS00071; HOMEOBOX-2; 1.
RT	Submitted (OCT-1994) to the EMBL/GenBank/DDBJ databases.	DR	PROSITE; PS00478; LIM_DOMAIN_1; 2.
RL	-1- SIMILARITY: CONTAINS 2 LIM DOMAINS. THE LIM DOMAIN BINDS 2 ZINC ZINC.	DR	PROSITE; PS50023; LIM_DOMAIN_2; 2.
CC		KW	DNA-binding; Homeobox; LIM domain; Metal-binding; Nuclear protein; Zinc.
CC	SEQUENCE: 400 AA; 44339 MW; F687E764F233CD4C CRC64;	KW	
CC	IONS.	SEQUENCE	
DR	EMBL; L35566; AAAS0258..1; -.	Query Match	83.7%; Score 36; DB 13; Length 400;
DR	HSSP; P32965; 1CTL.	Best Local Similarity	71.4%; Pred. No. 33;
DR	InterPro; IPR015156; Homeobox.	Matches	5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
DR	InterPro; IPR00047; RTH_repressor.	Qy	1 CEEDFYR 7
DR	InterPro; IPR01781; LIM.	Db	103 CKEDYR 109
DR	PFam; PF00046; homeobox; 1.		
DR	PFam; PF00412; LIM; 2.		
DR	PRINTS; PR00031; HTREPRESSR.	RESULT 14	
DR	PRINTS; PR000010; Homeobox; 1.	ID	Q9N9Y2
DR	PROSITE; PD00094; LIM; 2.	PRT	PRELIMINARY; 726 AA.
DR	SMART; SM00132; LIM; 2.	AC	Q2M9Y2;
DR	PROSITE; PS00027; HOMEOBOX-1; 1.	DT	01-OCT-2000 (TREMBLrel. 15, Created)
DR	PROSITE; PS50071; HOMEOBOX-2; 1.	DT	01-OCT-2000 (TREMBLrel. 15, Last sequence update)
DR	PROSITE; PS00478; LIM_DOMAIN_1; 2.	DT	01-JUN-2002 (TREMBLrel. 21, Last annotation update)
DR	PROSITE; PS50023; LIM_DOMAIN_2; 2.	DE	FH5..17 protein.
KW	DNA-binding; Homeobox; LIM domain; Metal-binding; Nuclear protein; Zinc.	GN	FH5..17.
KW		OS	Arabidopsis thaliana (Mouse-ear cress).
SQ	SEQUENCE: 378 AA; 42007 MW; 34220850FCEB82FFC CRC64;	OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
SQ	SEQUENCE: 378 AA; 42007 MW; 34220850FCEB82FFC CRC64;	OC	Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
SQ	SEQUENCE: 378 AA; 42007 MW; 34220850FCEB82FFC CRC64;	OX	NCBI_TAXID=3702;
Qy	1 CEEDFYR 7	RN	[1]
DR	101 CKEDYR 109	RP	SEQUENCE FROM N. A.
AC		RP	Federici N. A., Palm C. J., Conway A. B., Conn L., Hansen N. F., Altafai H., Araujo R., Huizar L., Rowley D., Buehler E., Dunn P., Gonzalez A., Kremenetskaia I., Kim C., Lenz C., Li J., Liu S., Lueros S., Schwartz J., Shinn P., Toriumi M., Vysotskaya V. S., Walker M., Yu G., Ecker J., Theologis A., Davis R. W.
DT	01-JAN-1998 (TREMBLrel. 05, Last sequence update)	RL	Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
DT	01-JAN-1998 (TREMBLrel. 05, Last sequence update)	DR	EMBL; AC011001; AAF63144..1; -.
DT	01-MAR-2002 (TREMBLrel. 20, Last annotation update)	DR	InterPro; IPR00432; MuDR.
DE	LIM homeodomain.	DR	InterPro; IPR004862; MuRA.
GN	LH-2A.	DR	InterPro; IPR01878; zf_f_CCHC.
OS	Gallus gallus (Chicken).	DR	PFam; PE03108; MuDR; 1.
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauia; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;	DR	PFam; PE00098; zf_CCHC; 1.
OC	Gallus.	DR	SMART; SM00343; Znf_C2HC; 1.
NCBI_TAXID=9031;		SQ	SEQUENCE: 726 AA; 82359 MW; 6B9A6133C3BBF5B2 CRC64;
OX	SEQUENCE FROM N. A.	Query Match	83.7%; Score 36; DB 10; Length 726;
OX	NCBI_TAXID=9031;	Best Local Similarity	85.7%; Pred. No. 62;
RN	[1]	Matches	6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
RP	TISSUE-LIMB BUD;	Qy	1 CEEDFYR 7
RX	MDLINE-97146014; PubMed=9299541;	Db	633 CEEDFYR 639
RA	Nohno T., Kawakami Y., Wada N., Ishikawa T., Ohuchi H., Noji S.;	RESULT 15	
RT	"Differential expression of the two closely related LIM-class homeobox genes LH-2A and LH-2B during limb development".	Q9PNX2	
RT	Biophys. Res. Commun. 238:506-511(1997).	AC	Q9PNX2;
RL	-1- SIMILARITY: CONTAINS 2 LIM DOMAINS. THE LIM DOMAIN BINDS 2 ZINC ZINC.	DT	01-OCT-2000 (TREMBLrel. 15, Created)
CC	IONS.	DT	01-OCT-2000 (TREMBLrel. 15, Last sequence update)
CC		DT	01-DEC-2001 (TREMBLrel. 19, Last annotation update)
DR	HSSP; P06601; 1IFL.	DE	Hypothetical protein Cj0963.
DR	InterPro; IPR01356; Homeobox.		

GN CJ0963
 OS Campylobacter jejuni.
 OC Bacteria; Proteobacteria; epsilon subdivision; Campylobacter group
 CC Campylobacter
 OX NCBI_TAXID=19;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=20150912; PubMed=10688204;
 RA Parkhill J., Wren B.W., Mungall K., Ketley J.M., Churcher C.,
 RA Basham D., Chillingworth T., Davies R.M., Feltwell T., Holroyd S.,
 RA Jagels K., Karlyshev A.V., Moule S., Pallen M.J., Penn C.W.,
 RA Quail M.A., Rajandream M.A., Rutherford K.M., van Vliet A.H.M.,
 RA Whitehead S., Barrell B.G.;
 RT "The genome sequence of the food-borne pathogen *Campylobacter jejuni*
 reveals hypervariable sequences.";
 RL Nature 403:665-668 (2000).
 EMBL: ALI39076; CAB73220.1.
 DR Hypothetical protein; Complete proteome.
 KW BFB9C487F8642706 CRC64;
 SQ SEQUENCE 202 AA; 23926 MW;

Query Match 81.48; Score 35; DB 16; Length 202;
 best Local Similarity 8.3%; Pred. No. 26;
 matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CEEDEFY 6
 1:1111
 Db 99 CDEDEFY 104

Search completed: February 12, 2003, 11:47:00
 Job time : 54.7333 secs